

# CAL/EPA UNIFIED PROGRAM POLICY MEMORANDUM

SUBJECT:  CAL/EPA UNIFIED PROGRAM POLICY FOR HAZARD CLASSIFICATION – SOLIDS & LIQUIDS – GUIDANCE	NUMBER:  UP-11-07
	DATE ISSUED:  06/07/12
REFERENCES:  California Health & Safety Code, Chapter 6.95, Article 1, Sections 25503.5(a)(1)(D)	EXPIRES:  UNTIL RESCINDED
	CATEGORY:  BUSINESS PLAN PROGRAM

## STATEMENT OF PURPOSE

To provide guidance to be used by Cal/EPA, CUPAs, and regulated businesses to ensure that critical information about regulated solids and liquids are consistently collected and reported.

## BACKGROUND

Cal/EPA oversees the administration of the Unified Hazardous Waste and Hazardous Materials Management Program (Unified Program), a legislatively created consolidation of six hazardous waste and materials programs administered by state and local agencies. The intent of the program is to improve consistency and uniformity in administration, permitting, inspection and enforcement. The Hazardous Materials Release Response Plans and Inventories Program (HMBP) is one of the six programs. Pursuant to the HMBP Program, each CUPA is required to inspect businesses that meet the requirements of the program. All businesses that handle hazardous materials in quantities equal to or greater than 55 gallons, 500 pounds, or 200 cubic feet of gas at standard temperature and pressure or quantities of extremely hazardous substances above the threshold planning quantity, are required to inventory their hazardous materials, develop a site map, develop an emergency plan and implement a training program for employees. Businesses must submit this information to the CUPAs. The CUPA verifies the information and provides it to agencies responsible for protection of public health, safety and the environment.

## ANALYSIS

Assembly Bill 408, Wieckowski (AB 408) was Chaptered by the Secretary of State as Chapter 603, Statutes of 2011 on October 8, 2011, and took effect immediately as an urgency statute. AB408 amends Chapter 6.95 of the Health and Safety Code by adding subparagraph (E) to paragraph (1) of subsection (a), section 25503.5. This section raised the reporting thresholds for certain solids and liquids from 500 pounds or 55 gallons to 5,000 pounds.

### Conditions of increased reporting threshold

In order to be eligible for the increased reporting threshold of total weight of 5,000 pounds provided under subparagraph (D), a substance must be:

- Either a solid or liquid;
- Classified as a hazard for purposes of 8 CCR 5194 solely as either an irritant or sensitizer; and
- Not be a hazardous waste (8 CCR 5194 (b)(5)(A)).

The Hazardous Materials Business Plan Technical Advisory Group (TAG) and the Hazardous Materials Steering Committee developed a standard for classifying solids and liquids. The Office of Environmental Health Hazard Assessment reviewed the standard and agreed with the result.

The attached guidance document is published for use by businesses and Unified Program Agencies.

### ACTION PLAN

1. The Guidance for Hazard Classification - Solids & Liquids guidance document will be available on-line at the Cal/EPA website.
2. CUPA's are encouraged to inform regulated businesses in their jurisdiction of this guidance document and to post or link to it on their websites.

### STATUTORY REFERENCES

California Health and Safety Code, Chapter 6.95, Article 1, Sections 25503.5

### Questions

Please direct all questions regarding this policy to Jim Bohon, Unified Program Manager at (916) 327-5097 or email [jbohon@calepa.ca.gov](mailto:jbohon@calepa.ca.gov).

  
\_\_\_\_\_  
Don Johnson, Assistant Secretary  
California Environmental Protection Agency

Attachment 1 – Guidance for Hazard Classification - Solids & Liquids  
Attachment 2 – Attachment 1. CLP Table Excerpts



Matthew Rodriguez  
Agency Secretary



## Guidance for Hazard Classification – Solids & Liquids

Pursuant to Health and Safety Code 25503.5(a)(1)(D)

### Background

Assembly Bill 408, Wieckowski (AB 408) was Chaptered by the Secretary of State as Chapter 603, Statutes of 2011 on October 8, 2011, and took effect immediately as an urgency statute. AB408 amends Chapter 6.95 of the Health and Safety Code (HSC) by adding the following subparagraph (D) to paragraph (1) of subsection (a), section 25503.5.

(D) A total weight of 5,000 pounds, if the hazardous material is a solid or liquid substance that is classified as a hazard for purposes of Section 5194 of Title 8 of the California Code of Regulations solely as an irritant or sensitizer, unless the administering agency finds, and provides notice to the business handling the product, that the handling of lesser quantities of that hazardous material requires the submission of a business plan, or any portion thereof, in response to public health, safety, or environmental concerns.

### Purpose

The Hazardous Material Business Plan Technical Advisory Group (HMBP TAG) has determined that guidance is needed for businesses and Unified Program Agencies (UPAs) to consistently classify solid or liquid substances pursuant to subparagraph (D). A business may choose not to perform this classification process if it is not seeking the increased reporting thresholds provided under subparagraph (D). In accordance with paragraph (3) of subsection (a) of section 25503.5, the UPA shall make the findings required by subparagraph (D) in consultation with the local fire chief.

### Definition of key terms<sup>1</sup>

“Substance” means”

Any element, chemical compound or mixture of elements and/or compounds.

“Health hazard” means:

A substance for which there is statistically significant evidence based on at least one study conducted in accordance with established scientific principles that acute or chronic health effects may occur in exposed employees. The term "health hazard" includes substances which are carcinogens, toxic or highly toxic agents, reproductive toxins, irritants, corrosives, sensitizers, hepatotoxins, nephrotoxins, neurotoxins, agents which act on the hematopoietic system, and agents which damage the lungs, skin, eyes, or mucous membranes. Further definitions and explanations of the scope of health hazards are listed in 8 CCR 5194(c) and Appendix A to Section 5194.

<sup>1</sup> Title 8 California Code of Regulations, Division 1, Chapter 4, Subchapter 7, Group 16, Article 109, Section 5194

“Physical hazard” means:

A substance for which there is scientifically valid evidence that it is a combustible liquid, a compressed gas, explosive, flammable, an organic peroxide, an oxidizer, pyrophoric, unstable (reactive) or water-reactive. Definitions of the specific categories of physical hazards are listed in 8 CCR 5194(c).

### **Conditions of increased reporting threshold**

In order to be eligible for the increased reporting threshold of total weight of 5,000 pounds provided under subparagraph (D), a substance must be:

- Either a solid or liquid;
- Classified as a hazard for purposes of 8 CCR 5194 solely as either an irritant or sensitizer; and
- Not be a hazardous waste (8 CCR 5194 (b)(5)(A)).

### **Discussion**

Subsection (d) of 8 CCR 5194 establishes the requirement and criteria for manufacturers and importers to evaluate the substances they produce or import to determine if they are hazardous. In addition, health hazards must be defined and determined as mandated in 8 CCR 5194 Appendices A and B. Employers are not required to evaluate substances unless they choose not to rely on the evaluation performed by the manufacturer or importer for the substance to satisfy this requirement. The results of hazard evaluations conducted by manufacturers and importers are provided to employers in the form of:

- Labels and Other Forms of Warning, pursuant to 8 CCR 5194(f); and
- Material Safety Data Sheets, pursuant to 8 CCR 5194(f).

Many substances that are irritants or sensitizers also have other health hazards or physical hazards and are therefore ineligible for the higher reporting threshold provided under subparagraph (D). For example, products containing silica have associated target organ effects or are listed as carcinogens. Refer to the OSHA webpage on silica<sup>2</sup> and interpretative letters<sup>3, 4</sup> for more information regarding silica.

Table 3.1 of Annex VI to Regulation (EC) No 1272/2008 contains the hazard classification and labeling requirements for certain substances which are legally binding within the European Union. Attachment 1 lists those substances in Table 3.1 for which the sole physical and health hazards as classified under the EC Regulation are as irritants and/or sensitizers (aquatic effects are not hazards for the purposes of 8 CCR 5194).<sup>5</sup>

<sup>2</sup> Occupational Safety and Health Administration, n.d., *Silica, Crystalline*, <http://osha.gov/dsg/topics/silicacrystalline/index.html>, (accessed November 14, 2011).

<sup>3</sup> Occupational Safety and Health Administration, *Label requirements for crystalline silica*, (February 11, 1991). [http://osha.gov/pls/oshaweb/owadisp.show\\_document?p\\_table=INTERPRETATIONS&p\\_id=20191](http://osha.gov/pls/oshaweb/owadisp.show_document?p_table=INTERPRETATIONS&p_id=20191), (accessed November 14, 2011).

<sup>4</sup> Occupational Safety and Health Administration, *Special emphasis program for silicosis* (March 27, 1998). <http://osha.gov/dsg/topics/silicacrystalline/index.html>, (accessed November 14, 2011).

<sup>5</sup> European Commission Joint Research Centre, n.d., (ESIS) European Chemical Substances Information System, CLP/GHS, (Classification, Labelling and Packaging of substances and mixtures); Annex VI, Table 3.1, <http://esis.jrc.ec.europa.eu/index.php?PGM=cla> (accessed February 1, 2012).

The following procedure is recommended to determine whether a substance on Attachment 1, or another substance or mixture of substances are classified solely as an irritant or sensitizer for the purposes of 8 CCR 5194.

### **Recommended Procedure for Determining Hazard Classes**

Review the Material Safety Data Sheet (MSDS) to classify the hazards of a candidate substance. The format and content of an MSDS varies according to the standard used in preparing it. Most are organized into 16 sections with common section headings. A *Comparison of MSDS/SDS Elements* in these different formats is available on the OSHA website<sup>6</sup>.

A partial list of pertinent MSDS elements for hazard classification is provided in the table below. Due to variation in formats, these elements may not be included on the MSDS or located in a different section. Although some MSDS elements such as DOT Label and Hazard Class are not directly referenced in 8 CCR 5194, they provide a method for quickly determining the physical or health hazards of a substance.

No.	MSDS Section <sup>7</sup>	Element	Requirement	Symbols Allowed <sup>8</sup>
1	2	Physical State	Must be a solid or liquid	
2	2, 3, 8, 11	Emergency Overview or Hazard Designation	Must not include any indication of hazards other than irritant or sensitizer (no indication of the following other physical or health hazards)	
			<b>Physical hazards:</b>	
			combustible liquid	
			compressed gas	
			explosive	
			flammable	
			organic peroxide	
			oxidizer	
			pyrophoric	
			unstable (reactive)	
			water-reactive	
			<b>Health hazards:</b>	
			carcinogen	
			corrosive	
			highly toxic	
			toxic	
			target organ effects (partial listing):	
			a. hepatotoxins	
			b. nephrotoxins	

<sup>6</sup> Occupational Safety and Health Administration, n.d., *A Guide to The Globally Harmonized System of Classification and Labelling of Chemicals (GHS)*, <http://www.osha.gov/dsg/hazcom/ghs.html#b>, (accessed November 14, 2011).

<sup>7</sup> Due to variation in formats, all elements may not be included on the MSDS or may be located in different sections than those listed on the table.

<sup>8</sup> If reported on MSDS.

No.	MSDS Section	Element	Requirement	Symbols Allowed
			c. neurotoxins	
			d. agents which act on the blood or	
			e. agents which damage the lung	
			f. reproductive toxins	
			g. cutaneous hazards	
			h. eye hazards	
3	2, 3, 8, 11	Potential Health Effects or Acute Health Effects	See No. 2 above	
4	2, 3, 8, 11	Acute Toxicity ( <i>cf. definition of "toxic" in Appendix A to 8 CCR 5194</i> )	If tested, narrative must not indicate acute health hazards other than irritation or sensitization. If numerical test results are presented here, results must exceed the following: Dermal LD <sub>50</sub> : > 1,000 mg/kg (rat) Oral LD <sub>50</sub> : > 500 mg/kg (rat) Inhalation LC <sub>50</sub> (1-hr): > 2,000 ppmv - or - > 20 mgL (rat)	
5	2, 3, 8, 11	Carcinogenicity	Must not be listed as a carcinogen by NTP, IARC, or OSHA	
6	2, 3, 8, 11	Reproductive Toxicity	If tested, narrative must not indicate reproductive or teratogenic effects	
7	2, 3, 8, 11	Target Organ Statement	Narrative must not indicate target organ hazards	
8	5	Flashpoint	If a liquid, the flashpoint must be exceed 200°F (93.3°C) or otherwise not meet the hazard of combustibility	
9	5	Flammability	Must be nonflammable. If tested, solids must not ignite and burn with a self-sustained flame at a rate greater than one-tenth of an inch per second along its major axis	
10	9	Physical State	See No. 1 above	
11	9	Flashpoint	See No. 8 above	
12	10	Stability (i.e., Instability, Reactivity)	Must be stable under normal ambient conditions of temperature and pressure, and hazardous polymerization will not occur under normal conditions of storage and use	
13	11	Acute Toxicity	See No. 2 above	
14	11	Eye Effects	See No. 2 above	
15	11	Skin Effects	See No. 2 above	
16	11	Carcinogenicity	See No. 5 above	
17	11	Reproductive Effects	See No. 6 above	

No.	MSDS Section	Element	Requirement	Symbols Allowed
18	11	Target Organs	See No. 7 above	
19	11	Teratogenic Effects & Mutagenicity	See No. 6 above	
20	14	DOT Label and Hazard Class	If reported, must be "Not Regulated" by the Department of Transportation	
21	15	SARA Title III Hazard Categories	If reported, must be either "no" to all hazard categories, or be limited to "immediate (acute) health hazard"	
22	15	WHMIS Hazard Symbol & Classification	If reported, must either be "none", or limited to "Class D-2B: Materials Causing Other Toxic Effects (Toxic)"	
23	15	EEC Label Symbol And Classification	If reported, must be limited to the hazard classes, signal words, hazard statements and symbols below	
			Respiratory Sensitizer Signal Word – Danger Hazard Statement – May cause allergy or asthmatic symptoms or breathing difficulties if inhaled	
			Skin Sensitizer Signal Word – Warning Hazard Statement – May cause an allergic skin reaction	
			Irritant Signal Word – Warning Hazard Statement – Causes skin irritation - or - Causes serious eye irritation	
			Mild Irritant Signal Word – Warning Causes mild skin irritation - or - Causes eye irritation	
			Risk Phrases (Any combination of the following): R36 Irritating to eyes.R37 Irritating to respiratory system. R38 Irritating to skin. R42 May cause sensitization by inhalation. R43 May cause sensitization by skin contact.	
24	16	HMIS Rating	If reported, must be no higher than "1" in the Health, Flammability and Physical Hazard/Reactivity ratings with no asterisk "*" indicating chronic health effects	
25	16	NFPA Codes	If reported, must be no higher than "1" in each of the Health, Flammability and Reactivity ratings	





Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling		Specific Conc. Limits, M-factors	Notes	ATP inserted/ATP Updated
				Hazard Class and Category Code(s)	Hazard Statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)			
016-035-00-X	pentasodium 5-amino-3-(4-(4-(6-chloro-4-(3-sulphonatamino)-1,3,5-triazin-2-ylamino)-2,5-dimethylphenylazo)-2,5-disulphonatophenylazo)-4-hydroxynaphthalene-2,7-disulphonate	400-120-7	-	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
016-040-00-7	reaction mass of disodium 6-(2,4-dihydroxyphenylazo)-3-(4-(4-(2,4-dihydroxyphenylazo)anilino)-3-sulphonatophenylazo)-4-hydroxynaphthalene-2-sulphonate and disodium 6-(2,4-diaminophenylazo)-3-(4-(4-(2,4-diaminophenylazo)anilino)-3-sulphonatophenylazo)-4-hydroxynaphthalene-2-sulphonate and trisodium 6-(2,4-dihydroxyphenylazo)-3-(4-(4-(7-(2,4-dihydroxyphenylazo)-1-hydroxy-3-sulphonato-2-naphthylazo)anilino)-3-sulphonatophenylazo)-4-hydroxynaphthalene-2-sulphonate	400-570-4	-	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
029-005-00-6	(tris(chloromethyl)phthalocyaninato)copper(II), reaction products with <i>N</i> -methylpiperazine and methoxyacetic acid	401-260-1	-	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
603-101-00-3	tetrahydro-2-isobutyl-4-methylpyran-4-ol, mixed isomers ( <i>cis</i> and <i>trans</i> )	405-040-6	-	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
606-141-00-X	sodium 3-(methoxycarbonyl)-4-oxo-3,4,5,6-tetrahydro-2-pyridinolate	418-410-7	-	Eye Irrit. 2	H319	GHS07 Wng	H319			ATP01/
611-038-00-8	trisodium 1-hydroxynaphthalene-2-azo-4'(5',5"-dimethylbiphenyl)-4"-azo(4"-phenyl)sulfonyloxybenzene)-2,2",4-trisulfonate	406-820-9	-	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
014-006-00-6	bis(4-fluorophenyl)-methyl-(1,2,4-triazol-4-ylmethyl)slane hydrochloride	401-380-4	-	Eye Irrit. 2 Aquatic Chronic 2	H319 H411	GHS07 GHS09 Wng	H319 H411			CLP00/
607-511-00-3	reaction mass of: 4-[(3-decyloxypropyl)(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)amino]-4-oxobutyric acid; 4-[(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)(3-oxylloxypropyl)amino]-4-oxobutyric acid	423-750-4	-	Eye Irrit. 2 Aquatic Chronic 2	H319 H411	GHS07 GHS09 Wng	H319 H411			ATP01/
611-150-00-7	tetralithium 2-[6-[7-[2-(carboxylato)phenylazo]-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4-hydroxy-1,3,5-triazine-2-ylamino]benzoate	440-460-3	-	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412			ATP01/

601-074-00-2	reaction mass of: 4-(2,3-trimethylcyclopent-3-en-1-yl)-1-methyl-2-oxabicyclo[2.2.2]octane; 1-(2,2,3-trimethylcyclopent-3-en-1-yl)-5-methyl-6-oxabicyclo[3.2.1]octane; spiro[cyclohex-3-en-1-yl-(4,5,6,6a-tetrahydro-3,6,6,6a-tetramethyl)-1,3'(3H)-[2H]cyclopentall]furan]; spiro[cyclohex-3-en-1-yl-(4,5,6,6a-tetrahydro-4,6,6,6a-tetramethyl)-1,3'(3H)-[2H]cyclopentall]furan]	422-040-1	-	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2	H319 H315 H411	GHS07 GHS09 Wng	H319 H315 H411			CLP00/
607-183-00-1	zinc 2-hydroxy-5-C <sub>11</sub> -sallylbenzoate	402-280-3	-	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2	H319 H315 H411	GHS07 GHS09 Wng	H319 H315 H411			CLP00/
020-003-00-0	reaction mass of: dicalcium bis(2-hydroxy-5-tetra-propenylphenylmethyl)methylamine)dihydroxide; tri-calcium tris(2-hydroxy-5-tetra-propenylphenylmethyl)methylamine)trihydroxide; poly[calcium ((2-hydroxy-5-tetra-propenyl-phenylmethyl)methylamine)hydroxide]	420-470-4	-	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317			CLP00/
650-042-00-4	reaction product of polyethylene-polyamine-(C <sub>6</sub> -C <sub>8</sub> )-alkylamides with monothio-(S)-alkyl phosphonates	417-450-2	-	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H319 H315 H317 H412	GHS07 Wng	H319 H315 H317 H412			CLP00/
016-050-00-1	potassium sodium 5-(4-chloro-6-(4-(4-chloro-6-(5-hydroxy-2,7-disulphonato-6-(2-sulphonatophenylazo)-4-naphthylamino)-1,3,5-triazin-2-ylamino)phenyl)-methyl)amino)-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(2-sulphonatophenylazo)naphthalene-2,7-disulphonat	402-150-6	-	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317			CLP00/
613-184-00-8	nitrotriethyleneammonio propane-2-ol 2-ethylhexanoate	413-670-8	-	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317			CLP00/
015-195-00-8	reaction mass of: potassium <i>o</i> -toluenephosphonate; potassium <i>m</i> -toluenephosphonate; potassium <i>p</i> -toluenephosphonate	433-860-4	-	Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H319 H317 H412	GHS07 Wng	H319 H317 H412			ATP01/
647-004-00-4	cellulases with the exception of those specified elsewhere in this Annex	-	-	Resp. Sens. 1	H334	GHS08 Dgr	H334		A	CLP00/
647-016-00-X	amylases with the exception of those specified elsewhere in this Annex	-	-	Resp. Sens. 1	H334	GHS08 Dgr	H334			CLP00/
016-036-00-5	tetrasodium 5-(4,6-dichloro-5-cyanopyrimidin-2-ylamino)-4-hydroxy-2,3-azodinaaphthalene-1,2,5,7-disulphonate	400-130-1	-	Resp. Sens. 1 Aquatic Chronic 2	H334 H411	GHS08 GHS09 Dgr	H334 H411			CLP00/
615-045-00-7	4,4'-methylene bis(3-chloro-2,6-diethylphenylisocyanate)	420-530-1	-	Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 4	H334 H317 H413	GHS08 Dgr	H334 H317 H413			ATP01/
603-203-00-8	(1R,3S,7R,8R,10R,13R)-5,5,7,9,9,13-hexamethyl-4,6-dioxatetracyclo[6.5.1.0 <sup>10,6</sup> .0 <sup>2,7</sup> ]tridecane	427-580-1	-	Skin Irrit. 2	H315	GHS07 Wng	H315			ATP01/

603-111-00-8	reaction mass of: 1-(1,1-dimethylpropyl)-4-ethoxy- <i>cis</i> -cyclohexane; 1-(1,1-dimethylpropyl)-4-ethoxy- <i>trans</i> -cyclohexane	426-530-6	-	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410	ATP01/
603-112-00-3	cyclopentyl 2-phenylethyl ether	428-340-9	-	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410	ATP01/
607-500-00-3	calcium 2,2-bis[(5-tetrapropylene-2-hydroxy)phenyl]ethanoate	421-670-4	-	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410	CLP00/
601-065-00-3	reaction mass of: (1 $\alpha$ ,3 $\alpha$ ,6 $\alpha$ )-2,2,3',7',7'-pentamethylspiro(1,3-dioxane-5,2'-norcarane); (1 $\alpha$ ,3 $\beta$ ,6 $\alpha$ )-2,2,3',7',7'-pentamethylspiro(1,3-dioxane-5,2'-norcarane)	416-930-9	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	CLP00/ATP01
603-138-00-4	reaction mass of 4 diastereoisomers of 2,7-dimethyl-10-(1-methyllethyl)-1-oxaspiro[4.5]deca-3,6-diene	412-460-3	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	CLP00/
603-234-00-7	(1 <i>R</i> ,4 <i>R</i> )-4-methoxy-2,2,7,7-tetramethyltricyclo[6.2.1.0(1,6)]undec-5-ene	444-480-3	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	ATP01/
607-174-00-2	reaction mass of dodecyl 3-(2,2,4,4-tetramethyl-21-oxo-7-oxa-3,20-diazadipiro[5,1,1,1,2]henicosan-20-yl)propionate and tetradecyl 3-(2,2,4,4-tetramethyl-21-oxo-7-oxa-3,20-diazadipiro[5,1,1,1,2]henicosan-20-yl)propionate	400-580-9	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	CLP00/
607-356-00-1	ethyl <i>trans</i> -2,2,6-trimethylcyclohexanecarboxylate	412-540-8	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	CLP00/
607-607-00-5	reaction mass of: calcium bis(C <sub>10-14</sub> branched alkyl salicylate); calcium bis(C <sub>18-30</sub> -alkyl salicylate); calcium C <sub>10-14</sub> branched alkyl/salicylate-C <sub>18-30</sub> -alkyl salicylate; calcium bis (C <sub>10-14</sub> branched alkyl phenolate); calcium bis (C <sub>18-30</sub> -alkyl phenolate); calcium C <sub>10-14</sub> branched alkyl/phenolate-C <sub>18-30</sub> -alkyl phenolate; C <sub>10-14</sub> branched alkyl phenol; C <sub>18-30</sub> -alkyl phenol	430-180-1	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	ATP01/

607-687-00-1	reaction mass of: 2-{3,6-bis[(2-ethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (2-10%); 2-{3,6-bis-[(2,3-dimethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (2-10%); 2-{3,6-bis-[(2,4-dimethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (2-10%); 2-{3,6-bis-[(2,5-dimethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (2-10%); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (7-20%); 2-{3-[(2,4-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (7-20%); 2-{3-[(2,5-dimethylphenyl)-methylamino]-6-[(2,4-dimethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (7-20%); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (7-20%); 2-{3-[(2,4-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylum-9-yl}-benzenesulfonate (7-20%);	442-800-6	-	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	-	-	ATP01/
613-233-00-2	2,2-dialkyl-4-hydroxymethyl-1,3-dioxolane; reaction products with ethylene oxide (alkyl is C <sub>12</sub> and the sum to C <sub>13</sub> , average degree of ethoxylation is 3.5)	430-580-4	-	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	-	-	ATP01/
616-162-00-6	isostearic acid monoisopropanolamide	431-540-9	-	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	-	-	ATP01/
649-007-00-6	fatty acids, tall-oil, reaction products with iminodietanol and boric acid	400-160-5	-	-	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	-	-	CLP00/
603-201-00-7	(E)-(7R,11R)-3,7,11,15-tetramethylhexadec-2-ene-1-ol	416-120-5	-	-	Skin Irrit. 2 Aquatic Chronic 4	H315 H413	GHS07 Wng	H315 H413	-	-	ATP01/
007-023-00-5	sodium 3,5-bis(3-(2,4-di-tert-pentylphenoxy)propylcarbamoyl)benzenesulfonate	405-510-0	-	-	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317	-	-	CLP00/
616-023-00-X	N-hexadecyl(or octadecyl)/N-hexadecyl(or octadecyl)benzamide	401-980-6	-	-	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317	-	-	CLP00/

604-062-00-5	2,4-dimethyl-6-(1-methyl-pentadecyl)phenol	411-220-5		Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410		CLP00/
607-290-00-3	reaction mass (ratio not known) of: ammonium 1-C <sub>4</sub> -C <sub>18</sub> -alkoxy-carbonyl-2-(3-allyloxy-2-hydroxypropoxy-carbonyl)ethane-1-sulfonate; ammonium 2-C <sub>4</sub> -C <sub>18</sub> -alkoxy-carbonyl-1-(3-allyloxy-2-hydroxypropoxy-carbonyl)ethane-1-sulfonate	410-540-2		Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410		CLP00/
042-004-00-5	Reaction product of ammonium molybdate and C <sub>2</sub> -C <sub>24</sub> -diethoxylated alkylamine (1.5-1:3)	412-780-3		Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H315 H317 H411	GHS07 GHS09 Wng	H315 H317 H411		CLP00/
016-058-00-5	thionyl chloride, reaction products with 1,3,4-thiadiazol-2,5-dithiol, <i>tert</i> -nonanethiol and C <sub>12-14</sub> - <i>tert</i> -alkylamine	404-820-3		Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H315 H317 H412	GHS07 Wng	H315 H317 H412		CLP00/
604-061-00-X	reaction mass of: 2-chloro-5- <i>sec</i> -tetradecylhydroquinones where <i>sec</i> -tetradecyl = 1-methyltridecyl; 1-ethylidodecyl; 1-propylundecyl; 1-butyldecyl; 1-pentylonyl; 1-hexyloctyl	407-740-7		Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H315 H317 H412	GHS07 Wng	H315 H317 H412		CLP00/
016-053-00-8	(C <sub>16</sub> or C <sub>18</sub> - <i>n</i> -alkyl)(C <sub>16</sub> or C <sub>18</sub> - <i>n</i> -alkyl)ammonium 2-((C <sub>16</sub> or C <sub>18</sub> - <i>n</i> -alkyl)(C <sub>16</sub> or C <sub>18</sub> - <i>n</i> -alkyl)carbamoyl)benzenesulphonate	402-460-1		Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4	H315 H317 H413	GHS07 Wng	H315 H317 H413		CLP00/
601-079-00-X	reaction mass of: <i>trans-trans</i> -cyclohexadeca-1,9-diene; <i>cis-trans</i> -cyclohexadeca-1,9-diene	429-620-3		Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4	H315 H317 H413	GHS07 Wng	H315 H317 H413		ATP01/
612-248-00-2	reaction product of diphenylamine, phenothiazine, and alkenes, branched (C <sub>8-10</sub> , C <sub>9</sub> -rich)	439-540-0		Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4	H315 H317 H413	GHS07 Wng	H315 H317 H413		ATP01/
016-039-00-1	tetrasodium 2-(6-chloro-4-(2,5-dimethyl-4-(2,5-disulphonatophenylazo)phenylazo)-3-ureidoanilino)-1,3,5-triazin-2-ylamino)benzene-1,4-disulphonate	400-430-2		Skin Sens. 1	H317	GHS07 Wng	H317		CLP00/
016-043-00-3	dilithium 6-acetamido-4-hydroxy-3-(4-(2-sulphonatoxy)ethylsulphonyl)phenylazo)naphthalen e-2-sulphonate	401-010-1		Skin Sens. 1	H317	GHS07 Wng	H317		CLP00/
027-008-00-7	complex of cobalt(III)-bis( <i>N</i> -phenyl-4-(5-ethylsulfonyl-2-hydroxyphenylazo)-3-hydroxynaphthylamide), hydrated (n H <sub>2</sub> O, 2<n<3)	427-390-9		Skin Sens. 1	H317	GHS07 Wng	H317		ATP01/

603-182-00-5	reaction product of saturated, monounsaturated and multiple unsaturated long-chained natty esterified alcohols of vegetable origin ( <i>Brassica napus</i> L., <i>Brassica rapa</i> L., <i>Helianthus annuus</i> L., <i>Glycine hispida</i> , <i>Gossypium hirsutum</i> L., <i>Cocos nucifera</i> L., <i>Elaeis guineensis</i> ) with <i>O,O</i> -disobutylidithiophosphate and 2-ethylhexylamine and hydrogen peroxide	428-630-5	-	Skin Sens. 1	H317	GHS07 Wng	H317					ATP01/
605-031-00-9	reaction mass of: 2,2-dimethoxyethanal [(this component is considered to be anhydrous in terms of identity, structure and composition. However, 2,2-dimethoxyethanal will exist in a hydrated form, 60% anhydrous is equivalent to 70.4% hydrate, water (including free water and water in hydrated 2,2-dimethoxyethanal)]	421-890-0	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
606-103-00-2	1-(4-( <i>trans</i> -4-ethylcyclohexyl)phenyl)ethanone	426-460-6	-	Skin Sens. 1	H317	GHS07 Wng	H317					ATP01/
607-182-00-6	methyl 3-sulphamoyl-2-thenoate	402-050-2	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
607-212-00-8	poly(oxypropyleneacarbonyl-co-oxyethylene)carbonyl, containing 27% hydroxyvalerate	403-300-3	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
607-285-00-6	reaction mass of: 7-(((3-aminophenyl)sulfonyl)amino)naphthalene-1,3-disulfonic acid; sodium 7-(((3-aminophenyl)sulfonyl)amino)-naphthalene-1,3-disulfonate; potassium 7-(((3-aminophenyl)sulfonyl)amino)-naphthalene-1,3-disulfonate	410-065-0	-	Skin Sens. 1	H317	GHS07 Wng						CLP00/
607-294-00-5	sodium 2-benzyloxy-1-hydroxyethane-sulfonate	410-680-4	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
607-298-00-7	2-(trimethylammonium)ethoxyacetate-benzene-4-sulfonate	411-010-3	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
607-329-00-4	reaction mass of: sodium 2-( <i>C<sub>12:18</sub>-n-alkyl</i> )amino-1,4-butanedioate; butanodioate; sodium 2-octadecenyl-amino-1,4-butanedioate	411-250-9	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
607-404-00-1	reaction mass of: (Z)-3,7-dimethyl-2,6-octadienyl)oxycarbonylpropanoic acid; di-((E)-3,7-dimethyl-2,6-octadienyl) butanodioate; di-((Z)-3,7-dimethyl-2,6-octadienyl) butanodioate; (Z)-3,7-dimethyl-2,6-octadienyl butanodioate; ((E)-3,7-dimethyl-2,6-octadienyl)oxycarbonylpropanoic acid	415-190-4	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/

607-468-00-0	reaction mass of: monosodium 4-((4-(5-sulfonato-2-methoxyphenylamino)-6-chloro-1,3,5-triazine-2-yl)amino)-2-((1,4-dimethyl-6-oxido-2-oxo-5-sulfonatomethyl)-1,2-dihydropyridine-3-yl)azo)benzenesulfonate;	419-450-8	-	Skin Sens. 1	H317	GHS07 Wng	H317	CLP000/
607-569-00-X	reaction mass of: sodium 2-amino-4-(2,6-difluoropyrimidin-4-ylamino)benzenesulfonate; sodium 2-amino-4-(4,6-difluoropyrimidin-4-ylamino)benzenesulfonate	426-470-0	-	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
607-585-00-7	strontium 2-((2-hydroxy-6-sulfonato-1-naphthyl)azo)naphthalene-1-sulfonate	427-930-3	-	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
607-610-00-1	trisodium 4-hydroxy-6-(sulfonatomethylamino)-5-(2-(2-sulfatoethylsulfonyl)phenyl)azobenzene-2-sulfonate	430-280-3	-	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
607-631-00-6	reaction mass of: 2-(2-((oxo(phenyl)acetyl)oxy)ethoxy)ethyl oxo(phenyl)acetate; (2-(2-hydroxyethoxy)ethyl) oxo(phenyl)acetate	442-300-8	-	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
609-073-00-9	lithium potassium sodium <i>N,N'</i> -bis(6-[7-(4-(4-chloro-1,3,5-triazin-2-yl)amino-4-(2-ureidophenyl)azobenzene-1,3,6-trisulfonato)] <i>N'</i> -(2-aminoethyl)piperazine	427-850-9	-	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
611-016-00-8	reaction mass of: 1,1'-((dihydroxyphenylene)bis(azo-3,1-phenyleneazo(1-(3-dimethylaminopropyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxopyridine-5,3-diy)))dipyrindinium dichloride dihydrochloride, mixed isomers and 1-(1-(3-dimethylaminopropyl)-5-(3-(4-(1-(3-dimethylaminopropyl)-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-5-pyridino-3-pyridyl)azo(phenyl)azo)-2,4(or 2,6 or 3,5)-dihydroxyphenyl)azo(phenyl)azo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-3-pyridyl)pyridinium dichloride	404-540-1	-	Skin Sens. 1	H317	GHS07 Wng	H317	CLP000/

611-018-00-9	tetrammonium 5-(4-(7-amino-1-hydroxy-3-sulfonato-2-naphthylazo)-6-sulfonato-1-naphthylazo)isophthalate	405-130-5	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
611-023-00-6	sodium 7-(4-(6-dichloro-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(4-(2-sulfonateoxy)ethylsulfonyl)phenylazo) naphthalene-2-sulfonate	404-600-7	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
611-036-00-7	2-(4-(5,6(or 6,7)-dichloro-1,3-benzothiazol-2-ylazo)- <i>N</i> -methyl- <i>m</i> -toluidino)ethyl acetate	405-440-0	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
611-074-00-4	reaction mass of: sodium/potassium (3-(4-(5-(5-chloro-2,6-difluoropyrimidin-4-ylamino)-2-methoxy-3-sulfonatophenylazo)-2-oxido)phenylazo)-2,5,7-trisulfonato-4-naphtholato)coppe(II); sodium/potassium (3-(4-(5-(5-chloro-4,6-difluoropyrimidin-2-ylamino)-2-methoxy-3-sulfonatophenylazo)-2-oxido)phenylazo)-2,5,7-trisulfonato-4-naphtholato)coppe(II)	407-100-7	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
611-107-00-2	potassium sodium 4-(4-chloro-6-(3,6-disulfonato-7-(5,8-disulfonato-naphthalen-2-ylazo)-8-hydroxy-naphthalen-1-ylamino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-(2-sulfatoethanesulfonyl)-phenylazo)-naphthalene-1,7-disulfonate	412-490-7	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
611-111-00-4	disodium 2-[[4-(2-chloroethylsulfonyl)phenyl]-(2-hydroxy-5-sulfo-3-[3-(2-(2-sulfooxy)ethylsulfonyl)ethylazo]-4-sulfobenzoato(3-couprate(1-))	414-230-8	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
611-112-00-X	tetrasodium 4-hydroxy-5-[4-[3-(2-sulfatoethanesulfonyl)phenylamino]-6-morpholin-4-yl-1,3,5-triazin-2-ylamino]-3-(1-sulfonatophthalen-2-ylazo)naphthalene-2,7-disulfonate	413-070-6	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
611-118-00-2	sodium 1,2-bis[4-[4-({4-(4-sulfonylazo)-2-sulfonylazo})-2-ureido-phenyl-amino]-6-fluoro-1,3,5-triazin-2-ylamino]propane, sodium salt	413-990-8	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
613-106-00-2	tetrapotassium 2-(4-(5-(1-(2,5-disulfonatophenyl)-3-ethoxy-carbonyl)-5-hydroxy-pyrazol-4-yl)pent-2,4-dienylidene)-3-ethoxy-carbonyl-5-oxo-2-pyrazolin-1-yl)benzene-1,4-disulfonate	405-240-3	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/
613-187-00-4	5-(2-amino-5-cyano-6-[2-(2-hydroxyethoxy)ethylamino]-4-methylpyridin-3-ylazo)-3-methyl-2,4-dicarboximidethiophene	410-530-8	-	Skin Sens. 1	H317	GHS07 Wng	H317					ATP01/
613-263-00-7	monosodium 3-cyano-5-fluoro-6-hydroxypyridine-2-olate	429-570-2	-	Skin Sens. 1	H317	GHS07 Wng	H317					ATP01/
616-027-00-1	tris(2-(2-hydroxyethoxy)ethyl)ammonium 3-acetoacetamido-4-methoxybenzenesulfonate	403-760-5	-	Skin Sens. 1	H317	GHS07 Wng	H317					CLP00/



616-047-00-0	reaction mass of 2,2',2'',2'''-(ethylenedinitriolotetakis- <i>N,N</i> -di(C <sub>16</sub> )alkyl)acetamide; 2,2',2'',2'''-(ethylenedinitriolotetakis- <i>N,N</i> -di(C <sub>18</sub> )alkyl)acetamide	-	-	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
051-006-00-5	diphenyl(4-phenylthiophenyl)sulfonium hexafluoroantimonate	403-500-0	-	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H400 H410				CLP00/
603-119-00-1	1,1'-(1,3-phenyleneedioxy)bis(3-(2-(prop-2- enyl)phenoxy)propan-2-ol)	403-840-5	-	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H400 H410				CLP00/
606-119-00-X	( <i>E</i> )-3-methyl-5-cyclopentadecen-1-one	429-900-5	-	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H400 H410				ATP01/
607-588-00-3	reaction mass of 2-ethylhexyl 2,3,4,5- tetrabromobenzoate; bis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate	428-050-2	-	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H400 H410				ATP01/
611-070-00-2	reaction mass of: disodium 6-(4-anisidino)-3- sulfonato-2-(3,5-dinitro-2-oxidophenylazo)-1- naphtholato(1-(5-chloro-2-oxidophenylazo)-2- naphtholato)chromate(1-); trisodium bis(5-(4-anisidino)-3-sulfonato-2-(3,5- dinitro-2-oxidophenylazo)-1-naphtholato)chromate(1- )	403-665-4	-	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H400 H410				CLP00/
611-148-00-6	reaction mass of: 2-(3-(2,6-dichloro-4- nitrophenylazo)carbazol-9-yl)ethanol; 2-(2-(3-(2,6-dichloro-4-nitrophenylazo)-carbazol-9- yl)-ethoxy)ethanol; 3-(2,6-dichloro-4-nitrophenylazo)carbazol	429-590-1	-	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H400 H410				ATP01/
613-085-00-X	reaction mass of 1,1'(methylenebis(4,1- phenylene)dipyrrole-2,5-dione and <i>N</i> -(4-(2,5- dioxopyrrol-1-yl)benzyl)phenyl)acetamide and 1-(4- (4-(5-oxo-2 <i>H</i> -2- furylidenamino)benzyl)phenyl)pyrrole-2,5-dione	401-970-1	-	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H400 H410				CLP00/
042-005-00-0	reaction mass of: mono- and di-glycerols of canola oil; canola oil acid amide of branched 1,3- propanediamine- <i>N</i> -(3-(tridecyloxy)propyl); <i>N,N</i> -diorgano dithiocarbamate molybdenum complex	434-240-6	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				ATP01/
603-228-00-4	(+/-)-(R*,R*-)6-fluoro-3,4-dihydro-2-oxiranyl-2 <i>H</i> -1- benzopyran; 6-fluoro-2-(2-oxiranyl)chromane	419-620-1	-	Skin Sens. 1 Aquatic Chronic 2-	H317 H411	GHS07 GHS09 Wng	H317 H411				ATP01/
605-027-00-7	reaction mass of: 3 <i>a</i> ,4,5,6,7,7 <i>a</i> -hexahydro-4,7- methano-1 <i>H</i> -indene-6-carboxaldehyde; 3 <i>a</i> ,4,5,6,7,7 <i>a</i> -hexahydro-4,7-methano-1 <i>H</i> -indene-5- carboxaldehyde	410-480-7	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/

605-034-00-5	reaction mass of: (1 <i>RS</i> , 2 <i>RS</i> , 3 <i>SR</i> , 6 <i>RS</i> , 9 <i>SR</i> )-9-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde; (1 <i>RS</i> , 2 <i>RS</i> , 3 <i>RS</i> , 6 <i>SR</i> )-8-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde; (1 <i>RS</i> , 2 <i>RS</i> , 4 <i>SR</i> , 6 <i>RS</i> , 8 <i>SR</i> )-8-methoxytricyclo[5.2.1.0(2,6)]decane-4-carbaldehyde	429-860-9	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
607-176-00-3	reaction mass of: $\alpha$ -3-(3-(2 <i>H</i> -benzotriazol-2-yl)-5- <i>tert</i> -butyl-4-hydroxyphenyl)propionyl- $\omega$ -hydroxypropyl(oxyethylene) and $\alpha$ -3-(3-(2 <i>H</i> -benzotriazol-2-yl)-5- <i>tert</i> -butyl-4-hydroxyphenyl)propionyl- $\omega$ -3-(3-(2 <i>H</i> -benzotriazol-2-yl)-5- <i>tert</i> -butyl-4-hydroxyphenyl)propionyl(oxyethylene)	400-830-7	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
607-188-00-9	hydrogen sodium <i>N</i> -carboxylatoethyl <i>N</i> -octadec-9-enylmaleamate	402-970-4	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
607-279-00-3	reaction mass of: <i>n</i> -octadecylaminoethyl bis(hydrogen maleate); <i>n</i> -octadecylaminoethyl hydrogen maleate hydrogenphthalate	405-960-8	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
607-295-00-0	reaction mass of: tetrasodium phosphonoethane-1,2-dicarboxylate; hexasodium phosphonobutane-1,2,3,4-tetra-carboxylate	410-800-5	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
607-301-00-1	reaction mass of: dodecanoic acid; poly(1- $\gamma$ )lactate esters of dodecanoic acid	411-860-5	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
607-672-00-X	reaction mass of: 2-hydroxy-3-(methacryloyloxy)propyl (2-benzoyl)benzoate; 1-hydroxyethyl-2-(methacryloyloxy)ethyl (2-benzoyl)benzoate; $\alpha$ -hydroxy- $\gamma$ -(methacryloyloxy)propyl( <i>or</i> -ethyl) (2-benzoyl)benzoate	419-000-0	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
607-678-00-2	reaction mass of: ethyl (2 <i>R</i> , 3 <i>R</i> )-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate; ethyl (2 <i>S</i> , 3 <i>S</i> )-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate	427-090-8	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
607-683-00-X	reaction mass of: methyl 3-( <i>Et</i> )-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate; methyl 3-((1 <i>Z</i> )-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate (20:80)	435-450-0	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/

CLP000/			H317 H411	GHS07 GHS09 Wng	H317 H411	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	CLP000/
611-017-00-3	2-(4-(diethylamino)propylcarbamoyl)phenylazo)-3-oxo-N-(2,3-dihydro-2-oxobenzimidazol-5-yl)butylamide	404-910-2								
611-085-00-4	reaction mass of: 3-cyano-5-(2-cyano-4-nitrophenylazo)-2-(2-hydroxyethylamino)-4-methyl-6-[3-(2-phenoxyethoxy)propylamino]pyridine; 3-cyano-5-(2-cyano-4-nitrophenylazo)-6-(2-hydroxyethylamino)-4-methyl-2-[3-(2-phenoxyethoxy)propylamino]pyridine; 3-cyano-5-(2-cyano-4-nitrophenylazo)-2-amino-4-methyl-6-[3-(2-hydroxypropoxy)propylamino]pyridine; 3-cyano-5-(2-cyano-4-nitrophenylazo)-6-amino-4-methyl-2-[3-(2-methoxypropoxy)propylamino]pyridine	411-880-4								
611-097-00-X	reaction mass of iron complexes of: 1,3-dihydroxy-4-[(5-phenylaminosulfonyl)-2-hydroxyphenylazo]-6-(5-amino-sulfonyl-2-hydroxyphenylazo)benzene and: 1,3-dihydroxy-4-[(5-phenylaminosulfonyl)-2-hydroxyphenylazo]-4-(4-nitro-2-sulfonylamino)phenylazo)benzene (t=2,5,6)	414-150-3								
611-104-00-6	reaction mass of: trisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(or 4(or 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(or 2 or 6)-(4-(4-nitro-2-sulfonatoanilino)phenylazo)phenolato)ferrate(1-); trisodium bis(2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)ferrate(1-); trisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(or 4 or 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(or 2 or 6)-(4-nitro-2-sulfonato)phenolato)ferrate(1-); trisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-oxidophenylazo)-5-hydroxyphenolato)(2(or 4 or 6)-(3,5-dinitro-2-oxidophenylazo)-5-hydroxy-4(or 2 or 6)-(3-sulfonato)phenolato)ferrate(1-); disodium 3,3'-(2,4-dihydroxy-1,3(or 1,5 or 3,5)-phenylenedio)di(benzenesulfonate)	406-870-1								
613-142-00-9	<i>trans</i> -N-methyl-2-styryl-4-aminomethine-(1-acetyl-1-(2-methoxyphenyl)acetamido)pyridinium acetate	405-860-4								

616-102-00-9	reaction mass of: $\alpha$ -[3-(3-mercaptopropoxy)carbamoyl]amino]methyl]phenylamino]carbamoyl]- $\omega$ -[3-(3-mercaptopropoxy)carbamoyl]amino]methyl]phenylamino]carbamoyloxy]-poly-(oxyethylene-co-oxypropylene); 1,2-(or 1,3-)bis[ $\alpha$ -(3-mercaptopropoxy)carbamoyl]amino]methyl]phenylamino]carbamoyl]- $\omega$ -oxy-poly(oxyethylene-co-oxypropylene)]-3-(or 2-)propanol; 1,2,3-tris[ $\alpha$ -(3-mercaptopropoxy)carbamoyl]amino]methyl]phenylamino]carbamoyl]- $\omega$ -oxy-poly-(oxyethylene-co-oxypropylene)]propanol]	415-870-0	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
616-127-00-5	reaction mass of: <i>N,N'</i> -Ethane-1,2-diy]bis(decanamide); 1,2-Hydroxy- <i>N'</i> -(2-[1-oxydecyl]amino)ethyl]octadecanamide; <i>N,N'</i> -Ethane-1,2-diy]bis(1,2-hydroxyoctadecanamide)	430-050-2	-	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
016-044-00-9	disodium <i>S,S</i> -hexane-1,6-diy]di(thiosulphate) dihydrate	401-320-7	-	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
024-019-00-9	Main component: acetoacetic acid anilide/3-amino-1-hydroxybenzene (ATAN-MAP); trisodium {} {6-[2 or 3 or 4]-amino-(4 or 5 or 6)-hydroxyphenylazo]-5-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato} {} {6'-[1-(phenylcarbamoyl)ethylazo]-5''-(phenylsulfamoyl)-3'-sulfonatonaphthalene-2''-azobenzene-1''2'''-diolato} {} chromate (III); by-product 1: acetoacetic acid anilide/acetoacetic acid anilide (ATAN-ATAN); trisodium bis {} {6-[1-(phenylcarbamoyl)ethylazo]-5-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato} {} chromate (III); by-product 2: 3-amino-1-hydroxybenzene/3-amino-1-hydroxybenzene (MAP-MAP); trisodium bis {} {6-[2 or 3 or 4]-amino-(4 or 5 or 6)-hydroxyphenylazo]-5-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato} {} chromate (III)	419-230-1	-	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
024-020-00-4	trisodium bis[3'-nitro-5'-sulfonato(6-amino-2-[4-(2-hydroxy-1-naphylazo)phenylsulfonamino]pyrimidin-5-azo)benzene-2',4'-diolato]chromate (III)	418-220-4	-	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
604-054-00-1	reaction mass of: 2-methoxy-4-(tetrahydro-4-methylene-2 <i>H</i> -pyran-2-yl)-phenol; 4-(3,6-dihydro-4-methyl-2 <i>H</i> -pyran-2-yl)-2-methoxyphenol	412-020-0	-	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/

607-173-00-7	dimethyl (3-methyl-4-(5-nitro-3-ethoxycarbonyl-2-thienyl)azo)phenylnitriodipropionate	400-460-6		Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412		CLP00/
607-409-00-9	reaction mass of: (3R)-[1S-(1 $\alpha$ , 2 $\alpha$ , 6R)-(2S)-2-methyl-1-oxo-butoxy)-8 $\alpha$ ]hexahydro-2,6-dimethyl-1-naphthalene]-3,5-dihydroheptanoic acid; inert biomass from <i>Aspergillus terreus</i>	415-840-7		Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412		CLP00/
607-561-00-6	sodium 4-hydroxy-3- $\alpha$ -(2-(2-hydroxyethyl)enesulfonyl)ethylureido)-5-nitrobenzenesulfonate	425-460-3		Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412		ATP01/
613-296-00-7	pentapotassium 2-(4-(5-[1-(2,5-disulfonatophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-methyl-1,3-pentadienyl)-3-methylcarbamoyl-5-oxidopyrazol-1-yl)benzene-1,4-disulfonate	418-270-7		Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412		ATP01/
604-035-00-8	4-nonylphenol, reaction products with formaldehyde and dodecane-1-thiol	404-160-6		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
606-123-00-1	4-hexadecyl-1-phenylpyrazolidin-3-one	430-840-7		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		ATP01/
607-217-00-5	2-ethoxyethyl 2-(4-(2,6-dihydro-2,6-dioxo-7-phenyl-1,5-dioxaindacen-3-yl)phenoxy)acetate	403-960-2		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
607-221-00-7	6-docosyloxy-1-hydroxy-4-(1-(4-hydroxy-3-methylphenanthren-1-yl)-3-oxo-2-oxaphthalen-1-yl)naphthalene-2-carboxylic acid	404-550-6		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
608-035-00-9	( $\pm$ )- $\alpha$ -(2-acetyl-5-methylphenyl)-amino]-2,6-dichlorobenzene-aceto-nitrile	419-290-9		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
612-267-00-6	bis(hydrogenated tallow C <sub>16,18</sub> -alkyl)hydroxylamine	418-370-0		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		ATP01/
613-100-00-X	2,9-bis(3-(diethylamino)propylsulfamoyl)quino(2,3-b)acridine-7,14-dione	404-230-6		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
613-300-00-7	1-imidazol-1-yl-octadecan-2-ol	434-120-3		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		ATP01/
616-071-00-1	reaction mass of: bis( <i>N</i> -cyclohexyl- <i>N</i> '-phenyleneureido)methylene; bis( <i>N</i> -octadecyl- <i>N</i> '-phenyleneureido)methylene; bis( <i>N</i> -dicyclohexyl- <i>N</i> '-phenyleneureido)methylene (1:2:1)	406-550-1		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
616-092-00-6	Polymeric reaction product of bicyclo[2.2.1]hepta-2,5-diene, ethene, 1,4-hexadiene, 1-propene with <i>N,N</i> -di-2-propenylformamide	404-035-6		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
616-198-00-2	1,3-bis[12-hydroxy-octadecamide- <i>N</i> -methylene]-benzene	423-300-7		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/
616-200-00-1	reaction mass of: <i>N,N'</i> -ethane-1,2-diybis(hexanamide); 12-hydroxy- <i>N</i> -[2-(1-oxohexyl)amino]ethyl]octadecanamide; <i>N,N'</i> -ethane-1,2-diybis(12-hydroxyoctadecanamide)	432-430-3		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		ATP01/

612-092-00-5	N,N'-Q2,2-dimethylpropylidene)hexamethylenediamine	401-660-6	1000-78-8	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317			CLP00/
607-191-00-5	isobutyl 3,4-epoxybutyrate	401-920-9	100181-71-3	Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410			CLP00/
017-013-00-2	calcium chloride	233-140-8	10043-52-4	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
607-580-00-X	ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate	422-360-1	100491-29-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
607-334-00-1	ethyl 1-ethyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate	405-880-3	100501-62-0	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
015-105-00-7	triphenyl phosphite	202-908-4	101-02-0	Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H315 H400 H410	GHS07 GHS09 Wng	H319 H315 H410		Skin Irrit. 2; H315: C ≤ 5 % Eye Irrit. 2; H319: C ≥ 5 %	CLP00/
613-053-00-5	antiazine (ISO); 2-chloro-N-(4,6-dichloro-1,3,5-triazin-2-yl)aniline	202-910-5	101-05-3	Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H315 H400 H410	GHS07 GHS09 Wng	H319 H315 H410			CLP00/
607-177-00-9	tribenuron methyl (ISO); 2-[4-methoxy-6-methyl-1,3,5-triazin-2-yl(methyl)carbamoylsulfamoyl]benzoic acid methyl ester, methyl 2-(3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-3-methylureidosulfonyl)benzoate	401-190-1	101200-48-0	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		N=100:	CLP00/ATP01
607-617-00-X	bis(2-ethylhexyl) 4,5-epoxycyclohexane-1,2-dicarboxylate	430-700-5	10138-36-0	Skin Sens. 1	H317	GHS07 Wng	H317			ATP01/
029-010-00-3	reaction mass of compounds from (dodecaakis(p-tolylthio)phthalocyaninato)copper(II) to (hexadecaakis(p-tolylthio)phthalocyaninato)copper(II)	407-700-9	101408-30-4	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
615-026-00-3	4,4'-methylenebis(2,6-dimethylphenyl cyanate)	405-790-4	101657-77-6	Skin Sens. 1	H317	GHS07	H317			CLP00/
014-033-00-4	2-(3,4-epoxycyclohexyl)ethyltriethoxy silane	425-050-4	10217-34-2	Aquatic Chronic 3 Skin Sens. 1	H412 H317	GHS07	H412 H317			ATP01/
613-113-00-0	2-(monophthalothio)benzothiazole	203-052-4	102-77-2	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H319 H315 H317 H411	GHS07 GHS09 Wng	H319 H315 H317 H411			CLP00/
616-050-00-7	lufenuron (ISO); N-[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)-phenyl-aminocarbonyl]-2,6-difluorobenzamide	410-690-9	103053-07-8	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			CLP00/
604-043-00-1	monobenzene, 4-hydroxyphenyl benzyl ether, hydroquinone monobenzyl ether	203-083-3	103-16-2	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317			CLP00/
603-136-00-4	3-((4-bis(2-hydroxyethyl)amino)-2-nitrophenyl)amino)-1-propanol	410-910-3	104226-19-9	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
611-101-00-X	2-(4-chloro-3-cyano-5-formyl-2-thienyl)azo-5-diethylaminoacetamide	405-200-5	104366-25-8	Skin Sens. 1	H317	GHS07	H317			CLP00/

607-399-00-6	2,2-dimethyl 3-methyl-3-butenyl propanoate	415-610-6	104468-21-5	Skin Irrit. 2 Aquatic Chronic 3	H315 H412	GHS07 Wng	H315 H412	CLP00/
016-087-00-3	reaction mass of: thiobis(4,1-phenylene)S,S',S'',S''-tetraphenyldisulfonium bishexafluorophosphate; diphenyl(4-phenylthiophenyl)sulfonium hexafluorophosphate; propylene carbonate	403-490-8	104558-95-4	Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H319 H317 H400 H410	GHS07 GHS09 Wng	H319 H317 H410	CLP00/
616-074-00-8	N-butyl-2-(4-morpholinylcarbonyl)benzamide	407-730-2	104958-67-0	Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H319 H317 H412	GHS07 Wng	H319 H317 H412	CLP00/
607-137-00-0	methyl acetate	203-299-8	105-45-3	Eye Irrit. 2	H319	GHS07 Wng	H319	CLP00/
603-079-00-5	2,2-(methylimino)diethanol; N-methyldiethanolamine	203-312-7	105-59-9	Eye Irrit. 2	H319	GHS07 Wng	H319	CLP00/
611-019-00-4	tetraalithium 6-amino-4-hydroxy-3-(7-sulfonato-4-(4-sulfonatophenylazo)-1-naphthylazo)naphthalene-2,7-disulfonate	405-150-4	106028-58-4	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
016-051-00-7	trisodium 7-(4-(6-fluoro-4-(2-(2-vinylsulfonyl)ethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulphonate	402-170-5	106359-91-5	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
613-084-00-4	2-(4-(3-(4-chlorophenyl)-4,5-dihydroprazolyl)phenylsulphonyl)ethyl dimethylammonium hydrogen phosphonate	402-490-5	106359-93-7	Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H400 H410	GHS07 GHS09 Wng	H319 H410	CLP00/
611-010-00-5	2-(2-cyano-4-(6-dimethylphenoxy)-5'-N,N-dipropylamino)propanamide	403-010-7	106359-94-8	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412	CLP00/
607-393-00-3	3-(cix-1-propenyl)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	415-750-8	106447-44-3	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
613-229-00-1	1-acetyl-4-(3-dodecyl-2,5-dioxo-1-pyrrolidinyl)-2,2,6,6-tetramethylpiperidine	411-930-5	106917-31-1	Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410	ATP01/
613-078-00-1	N,N,N-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine	401-990-0	106990-43-6	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	CLP00/
607-655-00-7	ethyl 6,8-dichlorooctanoate	435-080-1	1070-64-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	ATP01/
603-053-00-3	2-methylpentane-2,4-diol	203-489-0	107-41-5	Eye Irrit. 2 Skin Irrit. 2	H319 H315	GHS07 Wng	H319 H315	CLP00/
603-150-00-0	(±) trans-3,3-dimethyl-5-(2,2,3-trimethyl-cyclopent-3-en-1-yl)-pent-4-en-2-ol	411-580-3	107898-54-4	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410	CLP00/
607-194-00-1	propylene carbonate	203-572-1	108-32-7	Eye Irrit. 2	H319	GHS07 Wng	H319	CLP00/
016-045-00-4	lithium sodium hydrogen 4-amino-6-(5-(5-chloro-2,6-difluoropyrimidin-4-yl)amino)-2-sulphonatophenylazo)-5-hydroxy-3-(4-(2-(sulphonatooxy)ethylsulphonyl)phenylazo)naphthalen-2,7-disulphonate	6401-560-2	108624-00-6	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/

616-028-00-7	<i>N</i> -(4-(3-(4-cyanophenyl)ureido)-3-hydroxyphenyl)-2-(4-di- <i>tert</i> -pernylphenoxy)octanamide	408-020-5	108673-51-4	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			CLP00/
602-082-00-9	2,2,6,6-tetrakis(bromomethyl)-4-oxahexane-1,7-diol	408-020-5	109678-33-3	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
607-146-00-X	fumaric acid	203-743-0	110-17-8	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
613-101-00-5	<i>N</i> - <i>tert</i> -pernyl-2-benzothiazolesulfenamide	404-380-2	110799-28-5	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
603-083-00-7	1,1'-iminodipropen-2-ol; di-isopropoanilamine	203-820-9	110-97-4	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
613-097-00-5	7-amino-3-(3-carboxyurethyl)-4-methyl-1,3-thiazol-2-ylthio(methyl)-8-oxo-5-thia-1-azabicyclo(4,2,0)oct-2-ene-2-carboxylic acid	403-690-5	111298-82-9	Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3	H334 H317 H412	GHS08 Dgr GHS07 Wng	H334 H317 H412			CLP00/
603-081-00-6	2,2-dihydroethanol; thiodiglycol	203-874-3	111-48-8	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
607-185-00-2	ethyl <i>trans</i> -3-dimethylaminoacrylate	402-650-4	1117-37-9	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
616-088-00-4	2-aminothiopyran- <i>N,N</i> -dimethylfructosamide	413-440-7	112006-75-4	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
616-138-00-5	benzoic acid, <i>N</i> - <i>tert</i> -butyl- <i>N'</i> -(4-chlorobenzoyl)hydrazide	431-600-4	112226-61-6	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
603-096-00-8	2-(2-butoxyethoxy)ethanol; diethylene glycol monobutyl ether	203-961-6	112-34-5	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
606-063-00-6	( <i>E</i> )-3-(2-chlorophenyl)-2-(4-fluorophenyl)propanal	410-980-5	112704-51-5	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317			CLP00/
612-181-00-9	2-phenylthioaniline	413-030-8	1134-94-7	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
605-026-00-1	2,5,7,7-tetramethyloctanal	405-690-0	114119-97-0	Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H315 H317 H411	GHS07 GHS09 Wng	H315 H317 H411			CLP00/
611-012-00-6	reaction mass of 2,2-iminodietanol 6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazole-7-sulfonate and 2-methylaminoethanol 6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazole-7-sulfonate and <i>N,N'</i> -diethylpropane-1,3-diamine 6-methyl-2-(4-(2,4,6-triaminopyrimidin-5-ylazo)phenyl)benzothiazole-7-sulfonate	403-410-1	114565-65-0	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
607-661-00-X	1,1-dimethyl-ethyl 4-(bromomethyl)phenyl-2-carboxylate	442-850-9	114772-40-6	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			ATP01/
611-014-00-7	(tetrasodium 1-(4-(3-acetamido-4-(4'-nitro-2,2'-disulfonatosulfen-4-ylazo)amino)-6-(2,5-disulfonatoamino)-1,3,5-triazin-2-yl)-3-carboxypyridinium) hydroxide	404-250-5	115099-55-3	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
607-200-00-2	dodecyl 3,4,5-trihydroxybenzoate	214-620-6	1166-52-5	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/



611-015-00-2	tetrasodium 4-amino-5-hydroxy-6-(4-(2-(2-(sulfonatoxyethyl)sulfonyl)ethyl)carbamoyl)phenylazo)-3-(4-(2-(sulfonatoxyethyl)sulfonyl)phenylazo)naphthalene-2,7-disulfonate	404-320-5	116889-78-2	Skin Sens. 1	H317	GHS07 Wng	H317		CLP00/
611-039-00-3	7-((4,6-dichloro-1,3,5-triazin-2-yl)amino)-4-hydroxy-3-(4-(2-(sulfoxyethyl)sulfonyl)phenylazo)naphthalene-2-sulfonic acid	407-050-6	117715-57-8	Skin Sens. 1	H317	GHS07 Wng	H317		CLP00/
616-039-00-7	3',5'-dichloro-4'-ethyl-2'-hydroxy-palmitanilide	406-200-8	117827-06-2	Skin Sens. 1	H317	GHS07 Wng	H317		CLP00/
603-222-00-1	(2R,3S,4R,5R,7R,9R,10R,11S,12S,13R)-10-[(4-dimethylamino-3-hydroxy-6-methyltetrahydropyran-2-yl)oxy]-2-ethyl-3,4,12-trihydroxy-9-methoxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-1-oxacyclopentadecane	433-820-6	118058-74-5	Eye Irrit. 2	H319	GHS07 Wng	H319		ATP01/
607-250-00-5	4H-3,1-benzoxazine-2,4(1H)-dione	204-255-0	118-48-9	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317		CLP00/
607-223-00-8	transfluthrin (ISO); 2,3,6-tetrafluorobenzyl <i>trans</i> -2-(2,2-dichlorovinyl)-3,3-dimethylcyclopropanecarboxylate	405-060-5	118712-89-3	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410		CLP00/
602-066-00-1	tetrachloro- <i>p</i> -benzoquinone	204-274-4	118-75-2	Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H315 H400 H410	GHS07 GHS09 Wng	H319 H315 H410		CLP00/
601-045-00-4	1,2,3,4-tetrahydronaphthalene	204-340-2	119-64-2	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2	H319 H315 H411	GHS07 GHS09 Wng	H319 H315 H411	EU019	CLP00/
616-103-00-4	( <i>S,S'</i> )- <i>trans</i> -4-(acetylamino)-5,6-dihydro-6-methyl-7,7-dioxo-4 <i>H</i> -thieno[2,3- <i>b</i> ]thiopyran-2-sulfonamide	415-030-3	120298-38-6	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		CLP00/
005-009-00-3	tetrabutylammonium butyltriphenylborate	418-080-4	120307-06-4	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		CLP00/
613-135-00-0	di(benzothiazol-2-yl) disulfide	204-424-9	120-78-5	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		CLP00/
612-224-00-1	<i>N</i> ,2, <i>N</i> ,4,6-tetrakis(4-[(1,4-dimethylphenyl)amino]phenyl)-1,3,5-triazine-2,4,6-triamine	426-150-0	121246-28-4	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		ATP01/
612-242-00-X	cyprodime (ISO); 4-cyclopropyl-6-methyl- <i>N</i> -phenylpyrimidin-2-amine	-	121552-61-2	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	M=10;	ATP01/
612-014-00-X	sulphanilic acid; 4-aminobenzenesulphonic acid	204-482-5	121-57-3	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317		CLP00/
602-090-00-2	1-allyl-3-chloro-4-fluorobenzene	406-630-6	121626-73-1	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411		CLP00/
603-097-00-3	1,1,1'-nitritropropan-2-ol; trisopropanolamine	204-528-4	122-20-3	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412		CLP00/
616-045-00-X	2-(4-chloro-3-cyano-5-formyl-2-thienylazo)-5-(diethylamino)-2-methoxyacetamide	405-190-2	122371-93-1	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413		CLP00/

607-602-00-8	ethyl (3-cyanomethyl)-3,4-dihydro-4-oxophthalazine-1(4,2)-yl)acetate	429-680-0	12265-86-5	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			ATP01/
603-123-00-3	4-methyl-8-methylenetricyclo[3.3.1.1 <sup>3,7</sup> ]decan-2-ol	406-330-5	122760-84-3	Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H315 H317 H411	GHS07 GHS09 Wng	H315 H317 H411			CLP00/
607-336-00-2	4-methyl-8-methylenetricyclo[3.3.1.1 <sup>3,7</sup> ]dec-2-yl acetate	406-560-6	122760-85-4	Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H315 H317 H411	GHS07 GHS09 Wng	H315 H317 H411			CLP00/
612-115-00-9	dimethyl(dioctadecylammonium hydrogen sulfate	404-050-8	123312-54-9	Eye Irrit. 2 Aquatic Chronic 4	H319 H413	GHS07 Wng	H319 H413		Eye Irrit. 2; H319: C ≥ 10 %	CLP00/
603-016-00-1	4-hydroxy-4-methylpentan-2-one; diacetone alcohol	204-626-7	123-42-2	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
607-629-00-5	[[2-methyl-1-(1-oxopropoxy)propoxy][4-phenylbutyl]phosphiny] acetic acid	419-270-1	123399-82-6	Eye Irrit. 2	H319	GHS07 Wng	H319			ATP01/
611-028-00-3	C,C'-azodi(formamide)	204-650-8	123-77-3	Resp. Sens. 1	H334	GHS08 D <sub>pr</sub>	H334			CLP00/ATP01
607-144-00-9	adipic acid	204-673-3	124-04-9	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
616-061-00-7	N,N'-1,6-hexamethylbis[N-(2,2,6,6-tetramethyl-piperidin-4-yl)formamide	413-610-0	124172-53-8	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412			CLP00/
613-138-00-7	quinoxifen (SO); 5,7-dichloro-4-(4-fluorophenoxy)quinoline		124495-18-7	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410 H410			CLP00/
611-110-00-9	tetra-sodium/titium 4,4'-bis-(8-amino-3,6-disulfonato-1-naphthol-2-ylazo)-3-methylazobenzene	408-210-8	124605-82-9	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
603-070-00-6	2-amino-2-methylpropanol	204-709-8	124-68-5	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3	H319 H315 H412	GHS07 Wng	H319 H315 H412			CLP00/
613-160-00-7	(1S)-2-methyl-2,5-diazobicyclo[2.2.1]heptane dihydrobromide	411-000-9	125224-62-6	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
607-547-00-X	18-methylnonadecyl 2,2-dimethylpropanoate	424-370-1	125496-22-2	Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic	H315 H317 H413	GHS07 Wng	H315 H317 H413			ATP01/
616-153-00-7	4-methyl-3-oxo-N'-phenyl-2-(phenylmethyl)enepentanamide	425-860-8	125971-57-5	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
609-048-00-2	sodium 3-nitrobenzenesulphonate	204-857-3	127-68-4	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317			CLP00/
616-121-00-2	2,4-dihydroxy-N-(2-methoxyphenyl)benzamide	419-090-1	129205-19-2	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
616-093-00-1	Reaction products of aniline-terephthalaldehyde-toluidine condensate with maleic anhydride	406-620-1	129217-90-9	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
603-145-00-3	2-isopropyl-2-(1-methylbutyl)-1,3-dimethoxypropane	406-970-5	129228-11-1	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411			CLP00/
603-207-00-X	2-isobutyl-2-isopropyl-1,3-dimethoxypropane	430-800-9	129228-21-3	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411			ATP01/
616-082-00-1	N-(5-chloro-3-(4-(diethylamino)-2-methylphenyl)imino-4-methyl-6-oxo-1,4-cyclohexadien-1-yl)benzamide	413-200-1	129604-78-0	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/

603-068-00-5	2,3-epoxypropyl-2-ethylcyclohexyl ether; ethylcyclohexylglycidyl ether				Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317			CLP00/
607-320-00-5	bis[4-(ethenoxy)butyl] 1,3-benzenedicarboxylate	413-930-0	130066-37-8		Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			CLP00/
606-043-00-7	2,4-di- <i>tert</i> -butylcyclohexanone	405-340-7	13019-04-0		Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411			CLP00/
607-618-00-5	menadione sodium bisulfite; 2-naphthalenesulfonic acid, 1,2,3,4-tetrahydro-2- methyl-1,4-dioxo-, sodium salt	204-987-0	130-37-0		Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H315 H400 H410	GHS07 GHS09 Wng	H319 H315 H410			ATP01/
607-109-00-8	hexamethylene diacrylate; hexane-1,6-diol diacrylate	235-921-9	13048-33-4		Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317	D		CLP00/
606-096-00-6	3-(6- <i>O</i> -(6-deoxy- $\alpha$ - <small>D</small> -mannopyranosyl)- <small>O</small> -( $\alpha$ - <small>D</small> - glucopyranosyl)-( $\beta$ - <small>D</small> -glucopyranosyl)oxy)-2-(3,4- dihydroxyphenyl)-5,7-dihydroxy- <small>H</small> -1-benzopyran-4- one	424-170-4	130603-71-3		Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
027-003-00-X	cobalt sulfide	215-273-3	1317-42-6		Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	M=10:		CLP00/ATP01
607-337-00-7	reaction mass of: <i>trans</i> -4-acetoxy-4-methyl-2-propyl- tetrahydro-2 <i>H</i> -pyran, <i>cis</i> -4-acetoxy-4-methyl-2-propyl-tetrahydro-2 <i>H</i> - pyran	412-450-9	131766-73-9		Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
607-596-00-7	ethyl 2-(4-phenoxyphenyl)lactate	429-220-9	132584-17-9		Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			ATP01/
601-055-00-9	reaction mass of isomers of: mono-(2- tetradecyl)naphthalenes; di-(2-tetradecyl)naphthalenes; tri-(2-tetradecyl)naphthalenes	410-190-0	132983-41-6		Eye Irrit. 2 Aquatic Chronic 4	H319 H413	GHS07 Wng	H319 H413			CLP00/
607-360-00-3	sodium 3-acetoacetylaminoo-4-methoxytolyl-6- sulfonate	411-680-7	133167-77-8		Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
616-140-00-6	<i>N,N'</i> -(methylenedi-4,1-phenylene)bis[ <i>N'</i> -(4- methylphenyl)urea]	429-380-1	133336-92-2		Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			ATP01/
606-136-00-2	(3 <i>S</i> ,6 <i>R</i> ,9 <i>S</i> ,12 <i>R</i> ,15 <i>S</i> ,18 <i>R</i> ,21 <i>S</i> ,24 <i>R</i> )-6,18-dibenzyl- 3,9,15,21-tetraisobutyl-4,10,12,16,22,24-hexamethyl- 1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclo- tetracosane-2,5,8,11,14,17,20,23-octaoine	444-350-6	133413-70-4		Eye Irrit. 2 Aquatic Chronic 4	H319 H413	GHS07 Wng	H319 H413			ATP01/
611-091-00-7	sodium (1 <i>O</i> -1,95)lithium (0,05-1) 5-((5-(5-chloro-6- fluoro-pyrimidin-4-yl)amino)-2-sulfonatophenyl)azo)- 1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-3- pyridinemethylsulfonate	413-470-0	134595-59-8		Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
607-514-00-X	potassium <i>N</i> -(1-methoxy-1-oxobut-2-en-3-yl)valinate	427-240-2	134841-35-3		Skin Sens. 1	H317	GHS07 Wng	H317			ATP01/
607-521-00-8	tetraethyl <i>N,N'</i> -(methylenedicyclohexane-4,1- diyl)bis-di-aspartate	429-270-1	136210-30-5		Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			ATP01/
607-350-00-9	bis(4-(1,2-bis(ethoxycarbonyl)ethylamino)-3- methylcyclohexyl)methane	412-060-9	136210-32-7		Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/

611-105-00-1	sodium 4-(4-chloro-6-( <i>N</i> -ethylamino)-1,3,5-triazin-2-yl)-4,7,8-triazin-2-ylamino)-2-(1-(2-chlorophenyl)-5-hydroxy-3-methyl-1 <i>H</i> -pyrazol-4-yl)azo)benzenesulfonate		136213-75-7	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/
016-071-00-6	trisodium 3-amino-6,13-dichloro-10-(3-(4-chloro-6-(2-sulfophenylamino)-1,3,5-triazin-2-yl)amino)propyl) amino)-4,11-triphenoxydioxazinedisulfonate		136248-03-8	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
616-168-00-9	1-dimethylcarbamoyl-4-(2-sulfonatocetyl)pyridinium		136997-71-2	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
606-083-00-5	2-chloro-5-sec-hexadecylhydroquinone		407-750-1	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H319 H315 H317 H412	GHS07 Wng	H319 H315 H317 H412				CLP00/
015-192-00-1	tetrakis(2,6-dimethylphenyl)tri-phenylene biphosphate		432-770-2	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				ATP01/
616-079-00-5	1,6-hexanediyl-bis(2-(2-(1-ethylpentyl)-3-oxazolidinyl)ethyl)carbamate		411-700-4	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
611-081-00-2	tetrasodium 7-(2,5-dihydroxy- <i>KO</i> 2-7-sulfonato-6-(4-(411-470-5 (2,5,6-trichloro-pyrimidin-4-ylamino)phenyl)azo)-(N1,N7-N)-1-naphthyl)azo)-8-hydroxy- <i>KO</i> 8-naphthalene-1,3,5-trisulfonato(6-)]cuprate(II)		141048-13-7	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412				CLP00/
607-424-00-0	trifloxystrobin (TSO), ( <i>E,E</i> )- $\alpha$ -methoxyximinol-{}{2-[[[1-(3-(trifluoromethyl)phenyl]ethylidene)amino]oxy]methyl]benzenoic acid methyl ester		141517-21-7	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410 H410				CLP00/
005-012-00-X	diethyl[{}{4-[1,5,5-tris(4-diethylamino)phenyl]penta-2,4-dienylidene}cyclohexa-2,5-dienylidene}ammonium butyltriphenylborate		418-070-1	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410 H410				CLP00/
607-286-00-1	reaction mass of: sodium/potassium 7-[[[3-[[4-(2-hydroxy-naphthyl)azo]phenyl]azo]phenyl]sulfonyl]amino]-naphthalene-1,3-disulfonate		410-070-8	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412				CLP00/
016-069-00-5	3,5-bis (tetradecyloxy-carbonyl)benzenesulfonic acid		407-990-7	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/
607-609-00-6	ethyl (3 <i>R</i> )-4-cyano-3-hydroxybutanoate		430-220-6	Eye Irrit. 2	H319	GHS07 Wng	H319				ATP01/
613-271-00-0	trifosulfuron (FSO) (containing $\leq$ 0,02% AMTI); 1-[4-methoxy-6-(trifluoromethyl)-1,3,5-triazin-2-yl]-3-[2-(trifluoromethyl)benzenesulfonyl]urea (containing $\leq$ 0,02% AMTI)		142469-14-5	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410 H410			M=10:	ATP01/
616-042-00-3	<i>N</i> -(2-(6-ethyl-7-(4-methylphenoxy)- <i>H</i> -pyrazolo[1,5- <i>d</i> ]triazol-2-yl)propyl)-2-octadecyloxybenzamide		142859-67-4	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				CLP00/
613-148-00-1	tetrasodium 1,2-bis(4-fluoro-6-[5-(1-amino-2-sulfonatoacetyl)amino]-4-ylamino)-2,4,6-trimethyl-3-sulfonato)phenylamino]-1,3,5-triazin-2-ylamino)ethane		143683-23-2	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412				CLP00/

607-440-00-8	methyl 2-aminosulfanyl-6-(trifluoromethyl)pyridine- <i>c</i> carboxylate	144740-59-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	CLP00/
015-163-00-3	bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylphenylphosphin oxide	412-010-6	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	CLP00/
607-650-00-X	2-methyl-1,5-pentanediamine-1,3-benzenedicarboxylate	433-910-5	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
611-093-00-8	sodium 2-(4-(4-fluoro-6-(2-sulfo-ethylamino)-[1,3,5]triazin-2-ylamino)-2-ureido-phenylazo)-5-(4-sulfonylphenylazo)benzene-1-sulfonate	410-770-3	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
611-080-00-7	sodium 3-(2-acetamido-4-(4-(2-hydroxybutoxy)phenylazo)phenylazo)benzenesulfonate	410-150-2	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
607-515-00-5	reaction mass of: disodium hexyldiphenyl ether disulphonate; disodium dihexyldiphenyl ether disulphonate	429-650-7	Eye Irrit. 2 Aquatic Chronic 2	H319 H411	GHS07 GHS09 Wng	H319 H411	CLP00/
607-288-00-2	Tetrasodium ( <i>c</i> -3-(1-(3-( <i>e</i> -6-dichloro-5-cyanopyrimidinyl)(methylamino)propyl)-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo)-4-sulfonatophenylsulfamoyl)phthalocyanines <i>β</i> , <i>d</i> -trisulfonato( <i>o</i> -)nickelato II, where <i>a</i> is 1 or 2 or 3 or 4, <i>b</i> is 8 or 9 or 10 or 11, <i>c</i> is 15 or 16 or 17 or 18, <i>d</i> is 22 or 23 or 24 or 25 and where <i>e</i> and <i>f</i> together are 2 and 4 or 4 and 2 respectively	410-160-7	Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H319 H317 H412	GHS07 Wng	H319 H317 H412	CLP00/
602-097-00-0	1-bromo-9-(4,4,5,5-pentafluoropentylthio)nonane	422-850-5	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	CLP00/
607-475-00-9	reaction mass of: tetrasodium 7-(4-(4-chloro-6-[methyl-(3-sulfonatophenyl)amino]-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate; tetrasodium 7-(4-(4-chloro-6-[methyl-(4-sulfonatophenyl)amino]-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate (1:1)	412-940-2	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
613-108-00-3	benzothiazole-2-thiol	205-736-8	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	CLP00/
611-117-00-7	1,3-bis(1-(6-fluoro-4(1,5-disulfo-4-(3-aminocarbonyl)-1-ethyl-6-hydroxy-4-methyl-pyrid-2-on-5-ylazo)-phenyl-2-ylamino)-1,3,5-triazin-2-ylamino)} propane lithium-, sodium salt	415-100-3	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
611-096-00-4	methyl <i>N</i> -[3-acetylamino)-4-(2-cyano-4-nitrophenylazo)phenyl]- <i>N</i> -[(1-methoxy)acetyl]glycinate	413-040-2	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
607-355-00-6	<i>p</i> -tolyl 4-chlorobenzoate	411-530-0	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	CLP00/

613-192-00-1	3-benzyl- <i>exo</i> -6-nitro-2,4-dioxo-3-aza- <i>cis</i> -bicyclo[3.1.0]hexane	426-750-2	151860-15-0	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			ATP01/
611-138-00-1	2-(4-aminophenyl)-6- <i>tert</i> -butyl-1 <i>H</i> -pyrazolo[1,5- <i>b</i> ][1,2,4]triazole	415-910-7	152828-25-6	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09	H317 H411			CLP00/
016-068-00-X	sodium 3,5-bis(tetraethyloxy-carbonyl)benzenesulfonate	407-720-8	155160-86-4	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09	H317 H411			CLP00/
601-060-00-6	1,2-bis(4-fluoro-6-({14-sulfo-5-(2-(4-sulfonaphthalen-3-yl)azo)-1-hydroxy-3,6-disulfo-8-aminonaphthalene-7-yl)azo}phenylamino))-1,3,5-triazin-2-ylamino]ethane, x-sodium, y-potassium salts x = 7, y55 y = 0,245	417-610-1	155522-09-1	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
607-446-00-0	methyl 2-[4-(2-chloro-4-nitrophenyl)azo]-3-(1-oxopropyl)amino]phenylamino]propionate	416-240-8	155522-12-6	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			CLP00/
616-141-00-1	zoxamide (ISO); (R <i>S</i> )-3,5-dichloro- <i>N</i> -(3-chloro-1-ethyl-1-methyl-2-oxopropyl)- <i>p</i> -toluamide	-	156052-68-5	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	M=10:		ATP01/
609-071-00-8	reaction mass of: 2-methylsulfanyl-4,6-bis-(2-hydroxy-4-methoxy-phenyl)-1,3,5-triazine; 2-(4,6-bis-methylsulfanyl-1,3,5-triazin-2-yl)-5-methoxy-phenol	423-520-3	156137-33-6	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
607-111-00-9	2,2-bis(acryloyloxymethyl)butyl acrylate; trimethylolpropane triacrylate	229-701-3	15625-89-5	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317		D	CLP00/
607-271-00-X	2-isopropyl-5-methylcyclohexylloxycarbonyloxy-2-hydroxypropane	417-420-9	156324-82-2	Eye Irrit. 2 Aquatic Chronic 2	H319 H411	GHS07 GHS09	H319 H411			CLP00/
607-447-00-6	sodium 4-[4-(4-hydroxyphenyl)azophenylamino]-3-nitrobenzenesulfonate	416-370-5	156738-27-1	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			CLP00/
609-067-00-6	sodium and potassium 4-(3-aminopropylamino)-2,6-bis(3-(4-methoxy-2-sulfo-phenyl)azo)-4-hydroxy-2-sulfo-7-naphthylamino]-1,3,5-triazine	416-280-6	156769-97-0	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
608-049-00-5	2-(4-(4-butyl-(1-methylhexyl)amino)phenyl)-3-cyano-5-oxo-1,5-dihydro- <i>pyro</i> [2-y]lidene]propanedinitrile	429-180-2	157362-53-3	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			ATP01/
604-033-00-6	2-methyl-4-(1,1-dimethyl-ethyl)-6-(1-methyl-pentadecyl)-phenol	410-760-9	157661-93-3	Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410			CLP00/
601-039-00-0	methyl 2-benzylidene-3-oxobutylate	420-940-9	15768-07-7	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2	H319 H315 H411	GHS07 GHS09 Wng	H319 H315 H411			CLP00/
650-044-00-5	mixed linear and branched C <sub>4+5</sub> alcohols ethoxylated, reaction product with epichlorohydrin	420-480-9	158870-99-1	Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410			CLP00/
607-593-00-0	4-(2-methylacryloyloxy)phenyl 4-allyloxybenzoate	429-000-2	159235-16-2	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			ATP01/

611-078-00-6	(2,2'-(3,3'-dioxidobiphenyl-4,4'-diyl)diazo)bis(6-(4-(3-(407-240-9 (diethylamino)propylamino)-6-(3-( (diethylamino)propylamino)-1,3,5-triazin-2- ylamino)-3-sulfonato-1-naphtholato))dicopper(II) acetate lactate	159604-94-1	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/
603-217-00-4	2,4,6-tri- <i>tert</i> -butylphenyl 2-butyl-2-ethyl-1,3- propanediolphosphite	423-560-1	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				ATP01/
607-627-00-4	[(4 <i>S</i> ,5 <i>S</i> )-4-benzyl-2-oxo-5-oxazolidinylmethyl 4- nitrobenzenesulfonate	416-360-0	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
015-189-00-5	phenyl bis(2,4,6-trimethylbenzoyl)-phosphine oxide	423-340-5	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				CLP00/
603-110-00-2	reaction mass of <i>cis</i> -2-isobutyl-5-methyl 1,3- dioxane; <i>trans</i> -2-isobutyl-5-methyl 1,3-dioxane	426-130-1	Skin Irrit. 2 Aquatic Chronic 3	H315 H412	GHS07 Wng	H315 H412				ATP01/
016-079-00-X	<i>N,N</i> -bis(2-( <i>p</i> -toluenesulfonyloxy)ethyl) <i>p</i> - toluenesulfonamide	412-920-3	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				CLP00/
603-073-00-2	bis-[4-(2,3-epoxypropyl)phenyl]propane	216-823-5	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317		Eye Irrit. 2; H319; C ≥ 5 % Skin Irrit. 2; H315; C ≥ 5 %		CLP00/
607-126-00-0	2,2-(ethyleneedioxy)diethyl diacrylate; triethylene glycol diacrylate	216-853-9	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317			D	CLP00/
607-495-00-8	sodium 4-sulfophenyl-6-((1- oxononyl)amino)hexanoate	417-550-6	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
616-167-00-3	<i>N,N</i> -dibutyl-(2,5-dihydro-5-thioxo-1 <i>H</i> -tetrazol-1- yl)acetamide	418-290-6	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317				ATP01/
606-035-00-3	chloridazon (ISO); 5-amino-4-chloro-2-phenylpyridazine-3-( <i>H</i> )-one; pyrazon	216-920-2	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410				CLP00/
607-557-00-4	salt of: (1 <i>S-cis</i> )-1-amino-2,3-dihydro-1 <i>H</i> -inden-2-ol and [ <i>R</i> -[ <i>R</i> * <i>R</i> *]]-2,3-dihydroxybutanedioic acid	425-210-3	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
613-257-00-4	2-phthalimidoethyl- <i>N</i> -(4-(2-cyano-4- nitrophenylazo)phenyl)- <i>N</i> -methyl- $\beta$ -alaninate	426-400-9	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				ATP01/
612-211-00-0	<i>N</i> -[(benzotriazole-1-yl)methyl]-4- carboxybenzenesulfonamide	416-470-9	Eye Irrit. 2 Aquatic Chronic 2	H319 H411	GHS07 GHS09 Wng	H319 H411				CLP00/
601-047-00-5	<i>m</i> -mentha-1,3(8)-diene	404-150-1	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411				CLP00/
607-455-00-X	1-amino-4-(3-[4-chloro-6-(2,5-di-sulfophenylamino)- 1,3,5-triazin-2-ylamino]-2,2-dimethyl-propylamino)- anthraquinone-2-sulfonic acid, sodium/lithium salt	419-520-8	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411				CLP00/
607-453-00-9	4-benzyl-2,6-dihydroxy-4-aza-heptylene bis(2,2- dimethyloctanoate)	418-100-1	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				CLP00/
603-148-00-X	1,4-bis((vinyl)oxy)methylcyclohexane	413-370-7	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/

616-068-00-5	potassium 4-(1-methacrylamidoundecanamido)benzenesulfonate	406-500-9	174393-75-0	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
603-094-00-7	1,3-bis(2,3-epoxypropoxy)-2,2-dimethylpropane	241-536-7	17557-23-2	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317				CLP00/
605-035-00-0	(E)-3-(4-(4-fluorophenyl)-5-methoxymethyl)-2,6-bis(1-methoxymethyl)pyridin-3-yl)prop-2-enal	426-330-9	177964-68-0	Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 4	H319 H317 H413	GHS07 Wng	H319 H317 H413				ATP01/
014-011-00-3	cyclohexyldimethoxymethylsilane	402-140-1	17865-32-6	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411				CLP00/
612-215-00-2	3-chloro-2-(isopropylthio)aniline	421-700-6	179104-32-6	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411				CLP00/
014-007-00-1	triethoxyisobutylsilane	402-810-3	17980-47-1	Skin Irrit. 2	H315	GHS07 Wng	H315				CLP00/
611-130-00-8	tetra-ammonium 2-[(6-{7-(2-carboxylato-phenylazo)-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4-hydroxy-1,3,5-triazin-2-ylamino]benzoate	418-520-5	183130-96-3	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412				CLP00/ATP01
613-286-00-2	potassium 1-methyl-3-morpholinocarboxyl-4-[3-(1-methyl-3-morpholinocarboxyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate; [containing < 0.5 % N,N-dimethylformamide (EC no 200-679-5)]	418-260-2	183196-57-8	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
613-195-00-8	2,2-(1,4-phenylene)bis(4H-3,1-benzoxazine-4-one)	418-280-1	18600-59-4	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				CLP00/
612-223-00-6	N-benzyl-N'-ethyl-4-(5-nitro-benzof[isothiazol-3-ylazo]phenyl)amine	425-300-2	186450-72-7	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				ATP01/
607-473-00-8	pentacyclitol, dipentacyclitol, fatty acids, C <sub>10-16</sub> mixed esters with adipic acid, heptanoic acid and isostearic acid	426-590-3	187412-41-5	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
613-197-00-9	reaction mass of: 2,4,6-tri(tertbutylcarbamoyl)-1,3,5-triazine; 2,4,6-tri(methylcarbamoyl)-1,3,5-triazine; [(2-butyl-4,6-dimethyl)tricarbamoyl]-1,3,5-triazine; [(2,4-dibutyl-6-methyl)tricarbamoyl]-1,3,5-triazine	420-390-1	187547-46-2	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/
607-546-00-4	reaction mass of: methyl [(5-acetylamino-4-(2-chloro-2-nitrophenylazo)phenyl)methoxycarbonylmethylamino]acetate; methyl [(5-acetylamino-4-(2-chloro-4-nitrophenylazo)phenyl)ethoxycarbonylmethylamino]acetate	424-290-7	188070-47-5	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
608-016-00-5	1,4-Dicyano-2,3,5,6-tetra-chloro-benzene	401-550-8	1897-41-2	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410				CLP00/
014-028-00-6	α-[3-(1-oxoprop-2-enyl)-1-oxypropyl]dimethoxysilyloxy-ω-[3(1-oxoprop-2-enyl)-1-oxypropyl]dimethoxysilyl poly(dimethylsiloxane)	415-290-8	193159-06-7	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/



612-216-00-8	1-amino-1-cyanamino-2,2-dicyanoethylene, sodium salt	425-870-2	19450-38-5	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412	ATP01/
601-071-00-6	1-dimethoxymethyl-2-nitro-benzene	423-830-9	20627-73-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	CLP00/
605-029-00-8	2-cyclohexylpropanal	412-270-0	2109-22-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	CLP00/
616-182-00-5	N'-(1,3-dimethylbutylidene)-3-hydroxy-2-naphtholhydrazide	435-860-1	214417-91-1	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	ATP01/
606-058-00-9	4-fluoro-2,2-dimethoxyacetophenone	407-500-1	21983-80-2	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412	CLP00/
014-038-00-0	S-(3-(triethoxysilyl)propyl)octanethioate	436-690-9	220727-26-4	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
616-188-00-8	2-(5,5-dimethyl-2,4-dioxazolidin-3-yl)-4,4-dimethyl-3-oxo-N-(2-methoxy-5-octadecanoylamino)phenyl)pentanoic acid amide	443-980-9	221215-20-9	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413	ATP01/
606-105-00-3	3,4,3',4'-tetraphenyl-1,1'-ethandiyldibispyrol-2,5-dione	431-500-0	226065-73-2	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413	ATP01/
607-044-00-5	3,6-dichloro- <i>o</i> -anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro- <i>o</i> -anisate [2]	218-951-7 [1] 233-002-7 [2]	2300-66-5 [1] 10007-85-9 [2]	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412	CLP00/
607-684-00-5	alkenes, C <sub>12-14</sub> , hydroformylation products, disn. residues, C-(hydrogen sulfobutanediates), disodium salts	435-660-2	243662-07-1	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317	ATP01/
611-157-00-5	benzenesulfonic acid, 3,3'-(methylenebis(dihydroxyphenylene)azo)bis-, potassium sodium salt; potassium sodium 3-[(E)-(6-(3,4-dihydroxy-2-[(Z)-(3-sulfonatophenyl)diazenyl]benzyl))-2,3-dihydroxyphenyl]diazonyl]benzenesulfonate	432-590-4	243869-48-9	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412	ATP01/
603-074-00-8	reaction product: bisphenol-A-(epichlorhydrin); epoxy resin (number average molecular weight ≤ 700)	500-033-5	25068-38-6	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H319 H315 H317 H411	GHS07 GHS09 Wng	H319 H315 H317 H411	CLP00/
602-068-00-2	ethylene bis(trichloroacetate)	219-732-9	2514-53-6	Skin Irrit. 2	H315	GHS07 Wng	H315	CLP00/
607-437-00-1	3-(4-aminophenyl)-2-cyano-2-propenoic acid	417-480-6	252977-62-1	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
607-690-00-8	dimethyl[2S',2S']-6,6',6'-tetramethoxy-2,2'-[N,N'-bis(trifluoroacetyl)-S,S'-bi(L-homocysteiny)]dimino]dixanoate	432-860-1	255387-46-3	Skin Sens. 1	H317	GHS07 Wng	H317	ATP01/
603-120-00-7	2-methyl-5-phenylpentanol	405-890-8	25634-93-9	Eye Irrit. 2 Skin Irrit. 2	H319 H315	GHS07 Wng	H319 H315	CLP00/
613-059-00-8	profluralin (ISO); N-(cyclopropylmethyl)-α,α-trifluoro-2,6-dinitro-N-propyl-p-toluidine	247-656-6	26399-36-0	Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H400 H410	GHS07 GHS09 Wng	H319 H410	CLP00/
603-114-00-4	9-(2-propenyloxy)tricyclo[5.2.1.0(2,6)]dec-3(or-4)-ene	430-830-2	26912-64-1	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	ATP01/
616-083-00-7	[2-[(4-nitrophenyl)amino]ethyl]urea	410-700-1	27080-42-8	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412	CLP00/

015-191-00-6	dodecylidiphenyl phosphate	431-760-5	27460-02-2	Skin Irrit. 2	H315	GHS07	H315			ATP01/
605-024-00-0	2-bromo-5-hydroxy-4-methoxybenzaldehyde	426-540-0	2973-59-3	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09	H317 H411			ATP01/
616-030-00-8	ethidimuron (ISO); 1-(5-ethylsulphonyl-1,3,4-thiadiazol-2-yl)-1,3-dimethylurea	250-010-6	30043-49-3	Skin Sens. 1 Aquatic Acute 1	H317 H400	GHS07 GHS09	H317 H410			CLP00/
604-060-00-4	9,9-bis(4-hydroxyphenyl)fluorene	406-950-6	3336-71-3	Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H315 H400 H410	GHS07 GHS09 Wng	H319 H315 H410			CLP00/
605-033-00-X	reaction mass of: 3,7,11-trimethyl-6,10-dodecadienal; 3,7,11-trimethyl-7-oxo-6,10-dodecadienal	425-910-9	32480-08-3	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410			ATP01/
605-030-00-3	1-( <i>p</i> -methoxyphenyl)acetaldehyde oxime	411-510-1	3353-51-3	Skin Sens. 1	H317	GHS07	H317			CLP00/
607-267-00-8	<i>tert</i> -butyl (5 <i>S</i> , 6 <i>R</i> , 7 <i>R</i> )-3-bromomethyl-5,8-dioxo-7-(2-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate	407-620-4	33610-13-8	Resp. Sens. 1 Skin Sens. 1	H334 H317	GHS08 Dgr	H334 H317			CLP00/
604-070-00-9	triflosam; 2,4,4'-trichloro-2'-hydroxy-diphenyl-ether; 5-chloro-2-(2,4-dichlorophenoxy)phenol	222-182-2	3380-34-5	Aquatic Chronic 3 Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H412 H319 H315 H400	GHS07 GHS09 Wng	H319 H315 H410		M = 100:	CLP00/
616-194-00-0	2,2-diethoxy- <i>N,N'</i> -dimethylacetamide	449-950-1	34640-92-1	Eye Irrit. 2	H319	GHS07	H319			ATP01/
607-110-00-3	pentarythritol triacrylate	222-540-8	3524-68-3	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317		D	CLP00/
607-498-00-4	( <i>E</i> )-3,7-dimethyl-2,6-octadienylhexadecanoate	421-370-3	3681-73-0	Skin Irrit. 2 Aquatic Chronic 4	H315 H413	GHS07 Wng	H315 H413			CLP00/
647-003-00-9	cellulohydrolase, <i>exo</i> -	233-465-9	37329-65-0	Resp. Sens. 1	H334	GHS08	H334			CLP00/
607-374-00-X	5-amino-2,4,6-triiodo-1,3-benzene dicarbonyldichloride	417-220-1	37441-29-5	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09	H317 H411			CLP00/
607-669-00-3	methyl (9-acetoxy-3,8,10-triethyl-7,8,10-trimethyl-1,5-dioxo-9-aza-spiro[5.5]undec-3-yl)octadecanoate	445-990-9	376588-17-9	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			ATP01/
607-128-00-1	2- <i>tert</i> -butylaminoethyl methacrylate	223-228-4	3775-90-4	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317		D	CLP00/
612-175-00-6	2-( <i>O</i> -aminoxy)ethylamine dihydrochloride	412-310-7	37866-45-8	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317			CLP00/
613-118-00-8	flubenzamine (ISO); <i>N</i> -[3-phenyl-4,5-bis(trifluoromethyl)imino]thiazolidin-2-ylidene]aniline	253-703-1	37893-02-0	Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H400 H410	GHS07 GHS09 Wng	H319 H410			CLP00/
607-153-00-8	benzazolin (ISO); 4-chloro-2,3-dihydro-2-oxo-1,3-benzothiazol-3-ylacetic acid	223-297-0	3813-05-6	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3	H319 H315 H412	GHS07 Wng	H319 H315 H412			CLP00/
607-224-00-3	methyl 2-(3-nitrobenzylidene)acetate	405-270-7	39562-17-9	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			CLP00/

CLP00/	H317 H411	GHS07 GHS09 Wng	H317 H411	Skin Sens. 1 Aquatic Chronic 2	39562-27-1	400-650-9	403-620-3	40188-41-8	Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H315 H317 H411	GHS07 GHS09 Wng	H315 H317 H411	CLP00/
607-175-00-8													
608-022-00-8													
609-042-00-X													
606-057-00-3													
016-075-00-8													
602-103-00-1													
606-081-00-4													
601-081-00-0													
006-050-00-X													
011-005-00-2													
607-122-00-9													
607-564-00-2													
015-120-00-9													
603-052-00-8													
607-265-00-7													
616-087-00-9													
613-189-00-5													
601-072-00-1													
606-118-00-4													

016-026-00-0	sulphanilic acid; sulphanilic acid; sulfamic acid	226-218-8	5329-14-6	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3	H319 H315 H412	GHS07 Wng	H319 H315 H412			CLP00/
605-019-00-3	citral	226-394-6	5392-40-5	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317			CLP00/
607-338-00-2	(1 <i>S</i> ,3 <i>S</i> ,5 <i>R</i> ,6 <i>R</i> )-(4-nitrophenylmethyl)-1-dioxo-6-phenylacetamido-penam-3-carboxylate	412-670-5	54275-93-3	Resp. Sens. 1	H334	GHS08 Dgr	H334			CLP00/
607-274-00-6	2-( <i>N</i> -benzyl- <i>N</i> '-methylamino)ethyl 3-amino-2-butenoate	405-350-1	54527-73-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/
607-232-00-7	pyridate (S <sub>0</sub> ); <i>O</i> -(6-chloro-3-phenylpyridazin-4-yl)S-oxy thiocarbonate	259-686-7	5512-33-9	Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410			CLP00/
015-186-00-9	chlorpyrifos-methyl (S <sub>0</sub> ); <i>O</i> , <i>O</i> -dimethyl <i>O</i> -3,5,6-trichloro-2-pyridyl phosphorothioate	227-011-5	5598-13-0	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	M = 10000:		CLP00/
606-130-00-X	4-(1,4-dioxo-spiro[4.5]dec-8-yl)-cyclohexanone	423-860-2	56309-94-5	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			ATP01/
015-113-00-0	tolofos-methyl (S <sub>0</sub> ); <i>O</i> -(2,6-dichloro- <i>p</i> -tolyl)- <i>O</i> , <i>O</i> -dimethyl thiophosphate	260-515-3	57018-04-9	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			ATP01/
603-173-00-6	4,4-dimethyl-3,5,8-trioxabicyclo[5.1.0]octane	421-750-9	57280-22-5	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317			CLP00/
607-571-00-0	2-cyclopentane-1-acetic acid, 3-hydroxy-2-pentyl-, methyl ester acetate	431-400-7	57374-49-9	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
607-363-00-X	methyl-3-methoxyacrylate	412-900-4	5788-17-0	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
602-098-00-6	2-(3-bromophenoxy)tetrahydro-2 <i>H</i> -pyran	429-030-6	57999-49-2	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			ATP01/
015-160-00-7	vanadyl pyrophosphate	406-260-5	58834-75-6	Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H319 H317 H412	GHS07 Wng	H319 H317 H412			CLP00/
616-094-00-7	3,3'-di(2-chloroethyl)-1,1'-methylenebis(4,1-phenylene)dintra	406-370-3	58890-25-8	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			CLP00/
607-429-00-8	edetic acid; (EDTA)	200-449-4	60-00-4	Eye Irrit. 2	H319	GHS07 Wng	H319			ATP01/
616-160-00-5	2,2'-azobis( <i>N</i> '-(2-hydroxyethyl)-2-methylpropanamide)	429-090-3	61551-69-7	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			ATP01/
607-268-00-3	2-methylpropyl ( <i>R</i> ')-2-hydroxypropanoate	407-770-0	61597-96-4	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
607-386-00-2	dodecyl 3-amino-4-chlorobenzoate	428-020-9	6195-20-6	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			ATP01/
603-190-00-9	8,8-dimethyl-7-isopropyl-6,10-dioxaspiro[4.5]decane	424-030-2	62406-73-9	Skin Irrit. 2 Aquatic Chronic 3	H315 H412	GHS07 Wng	H315 H412			ATP01/
607-187-00-3	bis(2,2,6,6-tetramethyl-4-piperidyl) succinate	402-940-0	62782-03-0	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412			CLP00/
612-144-00-7	flumetralin (S <sub>0</sub> ); <i>N</i> -(2-chloro-6-fluorobenzyl)- <i>N</i> -ethyl- $\alpha,\alpha$ -trifluoro-2,6-dinitro- <i>p</i> -toluidine		62924-70-3	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H319 H315 H317 H400 H410	GHS07 GHS09 Wng	H319 H315 H317 H400 H410			CLP00/

607-614-00-3	2-(10-oxo-10H-9-oxa-10-phosphaphenanthren-10-ylmethyl)succinic acid	426-480-5	63562-33-4	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412	H317 H412	ATP01/
607-222-00-2	6-(2,3-dimethylmaleimido)hexyl methacrylate	404-870-6	63740-41-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	H317 H411	CLP00/
603-149-00-5	reaction mass of diastereoisomers of 1-(1-hydroxyethyl)-4-(1-methylethyl)cyclohexane	407-640-3	63767-86-2	Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2	H319 H315 H411	GHS07 GHS09 Wng	H319 H315 H411	H319 H315 H411	CLP00/
616-170-00-X	(2R)-2-amino-2-phenylacetamide	420-370-0	6485-67-2	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317	H319 H317	ATP01/
606-132-00-0	(6P)-6,19-epoxyandrost-4-ene-3,17-dione	433-490-3	6563-83-3	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412	H317 H412	ATP01/
604-039-00-X	ethyl 2-[4-[(6-chlorobenzoxazol-2-yl)oxy]phenoxy]propanoate; fenoxaprop-ethyl	266-362-9	66441-23-4	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410 H410	H317 H410 H410	CLP00/
607-275-00-1	sodium benzoyloxybenzene-4-sulfonate	405-450-5	66531-87-1	Skin Sens. 1	H317	GHS07 Wng	H317	H317	CLP00/
603-170-00-X	reaction mass of: 2-methyl-1-(6-methylbicyclo[2.2.1]hept-5-en-2-yl)pent-1-en-3-ol; 2-methyl-1-(1-methylbicyclo[2.2.1]hept-5-en-2-yl)pent-1-en-3-ol; 2-methyl-1-(5-methylbicyclo[2.2.1]hept-5-en-2-yl)pent-1-en-3-ol	415-990-3	67739-11-1	Eye Irrit. 2 Aquatic Chronic 2	H319 H411	GHS07 GHS09 Wng	H319 H411	H319 H411	CLP00/
603-103-00-4	oxirane, mono[(C <sub>12-14</sub> -alkyloxy)methyl] derivs.	271-846-8	68609-97-2	Skin Irrit. 2 Skin Sens. 1	H315 H317	GHS07 Wng	H315 H317	H315 H317	CLP00/
608-029-00-6	1,2-dihydro-6-hydroxy-4-methyl-1-[3-(1-methylethoxy)propyl]-2-oxo-3-pyridinecarbonitrile	411-990-2	68612-94-2	Skin Sens. 1	H317	GHS07 Wng	H317	H317	CLP00/
607-342-00-5	4-chlorobutyl veratrate	410-950-1	69788-75-6	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	H317 H411	CLP00/
606-117-00-9	2,6-bis(1,1-dimethylethyl)-4-(phenylenemethylene)cyclohexa-2,5-dien-1-one	429-460-4	7078-98-0	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413	H317 H413	ATP01/
607-489-00-5	reaction mass of: 2-ethylhexyl linolenate, linoleate and oleate; 2-ethylhexyl epoxyoleate; 2-ethylhexyl diepoxylinoleate; 2-ethylhexyl triepoxylinolenate	414-890-7	71302-79-9	Skin Sens. 1	H317	GHS07 Wng	H317	H317	CLP00/
607-570-00-5	sodium (6R- <i>trans</i> )-7-amino-8-oxo-3-[[[1-(sulfonemethyl)-1H-tetrazol-5-yl]thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate monohydrate	426-520-1	71420-85-4	Skin Sens. 1	H317	GHS07 Wng	H317	H317	ATP01/
616-137-00-X	4-dichloroacetyl-1-oxa-4-azaspiro[4.5]decane	401-130-4	71526-07-3	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	H317 H411	ATP01/
031-007-00-0	bis(4-dodecylphenyl)iodonium hexafluoroantimonate	404-420-9	71786-70-4	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412	H317 H412	CLP00/
616-012-00-X	N-(dichlorofluoromethylthio)phthalimide; N-(fluorodichloromethylthio)phthalimide	211-952-3	719-96-0	Skin Irrit. 2	H315	GHS07 Wng	H315	H315	CLP00/
607-338-00-3	2-methylpropyl 2-hydroxy-2-methylbut-3-enoate	406-235-9	72531-53-4	Eye Irrit. 2 Skin Irrit. 2	H319 H315	GHS07 Wng	H319 H315	H319 H315	CLP00/

607-654-00-1	(S)-3-hydroxy-γ-butyrolactone	434-990-4	7331-52-4	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
607-619-00-0	metanone nicotinamide bisulfite; 1,2,3,4-tetrahydro-2-methyl-1,4-dioxonaphthalene-2-sulfonic acid, compound with nicotin-3-amide (1:1)	277-543-7	73581-79-0	Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H315 H400 H410	GHS07 GHS09 Wng	H319 H315 H410				ATP01/
601-056-00-4	reaction mass of isomers of: methyl(diphenyl)methane; dimethyl(diphenyl)methane	405-470-4	73807-39-3	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410				CLP00/
612-132-00-1	<i>N,N'</i> -diphenyl- <i>p</i> -phenylenediamine; <i>N,N'</i> -diphenyl-1,4-benzenediamine	200-806-4	74-31-7	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412				CLP00/
606-088-00-2	2,4,7-tetramethyl-6-octen-3-one	422-520-0	74338-72-0	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411				CLP00/
613-211-00-3	<i>N</i> -methyl-4- <i>β</i> -formylstyryl)pyridinium methylsulfate	418-240-3	74401-04-0	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412				CLP00/
027-001-00-9	cobalt	231-158-0	7440-48-4	Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 4	H334 H317 H413	GHS08 Dgr	H334 H317 H413				CLP00/
608-033-00-8	<i>N</i> -butyl-3-(2-chloro-4-nitrophenyl)hydrazono)-1-cyano-2-methylprop-1-ene-1,3-dicarboximide	407-970-8	75511-91-0	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412				CLP00/
613-122-00-X	dichlorotriazole (ISO); ( <i>R</i> *, <i>R</i> *)-(±)-β-(2,4-dichlorophenyl)methyl]-α-(1,1-dimethylethyl)- <i>H</i> -1,2,4-triazole-1-ethanol; (2 <i>RS</i> , 3 <i>RS</i> )-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1 <i>H</i> -1,2,4-triazol-1-yl)pentan-3-ol		75736-33-3	Eye Irrit. 2 Aquatic Chronic 2	H319 H411	GHS07 GHS09 Wng	H319 H411				CLP00/
607-339-00-8	(1 <i>S</i> ,4 <i>R</i> , 6 <i>R</i> )-7 <i>R</i> -(4-nitrophenylmethyl)-3-methylene-1-(1,2-oxo-7-phenylacetamido-cepham-4-carboxylate)-penam-3-carboxylate	412-800-0	76109-32-5	Resp. Sens. 1	H334	GHS08 Dgr	H334				CLP00/
613-107-00-8	hexasodium 2,2'-vinylenebis(3-sulfonato-4,1-phenylene)imino(6- <i>β</i> -cyanomethyl- <i>N</i> -(2-hydroxypropyl)amino)-1,3,5-triazine-4,2-diy)imino)dibenzene-1,4-disulfonate	405-280-1	76508-02-6	Eye Irrit. 2	H319	GHS07 Wng	H319				CLP00/
613-186-00-9	(2 <i>R</i> ,3 <i>R</i> )-3-(( <i>R</i> )-1-( <i>tert</i> -butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl acetate	408-050-9	76855-69-1	Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2	H319 H317 H411	GHS07 GHS09 Wng	H319 H317 H411				CLP00/
601-051-00-7	4-phenylbut-1-ene	405-980-7	768-56-9	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411				CLP00/
016-094-00-1	sulfur	231-722-6	7704-34-9	Skin Irrit. 2	H315	GHS07 Wng	H315				ATP01/
606-104-00-8	1-(4-( <i>trans</i> -4-pentylcyclohexyl)phenyl)ethanone	426-830-7	78531-59-6	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				ATP01/
601-066-00-9	1-(4-( <i>trans</i> -4-heptylcyclohexyl)phenyl)ethanone	426-820-2	78531-60-9	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				CLP00/
606-049-00-X	4-( <i>trans</i> -4-propylcyclohexyl)acetophenone	406-700-6	78531-61-0	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413				CLP00/
613-219-00-7	7a-ethyl-3,5-is(1-methyl-2-yl)-2,3,4,5-tetrahydrooxazolol[3,4- <i>cj</i> -2,3,4,5-tetrahydrooxazole	417-140-7	79185-77-6	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411				CLP00/

603-186-00-7	trans-(5 <i>RS</i> ,6 <i>SR</i> )-6-amino-2,2-dimethyl-1,3-dioxepan-5-ol	419-050-3	79944-37-9	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
647-017-00-5	laccase	420-150-4	80498-15-3	Resp. Sens. 1	H334	GHS08 Dgr	H334	ATP01/
650-015-00-7	rosin; colophony	232-475-7 232-484-6 277-299-1	8050-09-7 8052-10-6 73138-82-6	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
607-353-00-5	reaction mass of: ethyl <i>exo</i> -tricyclo[5.2.1.0 <sup>2,6</sup> ]decane-2-carboxylate; ethyl <i>endo</i> -tricyclo[5.2.1.0 <sup>2,6</sup> ]decane- <i>exo</i> -2-carboxylate	407-520-0	80657-64-3	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411	CLP00/
613-126-00-1	imazapyr (ISO); 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo- <i>H</i> -imidazol-2-yl]-3-pyridine carboxylate		81334-34-1	Eye Irrit. 2 Aquatic Chronic 3	H319 H412	GHS07 Wng	H319 H412	CLP00/
607-644-00-7	methyl 2,2-dimethyl-6-methylcyclohexanecarboxylate	432-350-9	81752-87-6	Skin Irrit. 2	H315	GHS07 Wng	H315	ATP01/
016-034-00-4	tetrasodium 3,3'-(piperazine-1,4-diy)bis(6-chloro-1,3,5-triazine-2,4-diy)imino(2-acetamido)-4,1-phenyleneazo)bis(naphthalene-1,5-disulphonate)	400-010-9	81898-60-4	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
613-238-00-0	sodium 2-[[4-(6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]sulfonylethyl sulfate	430-890-1	81992-66-7	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	ATP01/
609-043-00-5	quintozene (ISO); pentachloronitrobenzene	201-435-0	82-68-8	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410	CLP00/
607-178-00-4	methyl $\alpha$ -(4,6-dimethoxy-pyrimidin-2-yl)ureidosulphonyl- <i>o</i> -toluate	401-340-6	83055-99-6	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	CLP00/
606-106-00-9	1-(4-( <i>trans</i> -4-butylecyclohexyl)phenyl)ethanone	427-320-7	83626-30-6	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413	ATP01/
601-038-00-5	di- <i>L</i> -para-menthene	417-870-6	83648-84-4	Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410	CLP00/
613-156-00-5	2-butyl-4-chloro-5-formylimidazole	410-260-0	83857-96-9	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411	CLP00/
607-186-00-8	quinclorac (ISO); 3,7-dichloroquinoline-8-carboxylic acid	402-780-1	84087-01-4	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
613-093-00-3	hexasodium 6,13-dichloro-3,10-bis((4-(2,5-disulfonatoamino)-6-fluoro-1,3,5-triazin-2-ylamino)prop-3-ylamino)-5,12-dioxa-7,14-diazapentacene-4,11-disulfonate	400-050-7	85153-92-0	Resp. Sens. 1 Skin Sens. 1	H334 H317	GHS08 Dgr	H334 H317	CLP00/
016-047-00-5	hexasodium 7-(4-(4-(2,5-disulfonatoamino)-6-fluoro-1,3,5-triazin-2-ylamino)-2-methylphenylazo)-7-sulphonatophenylazobis(naphthalene-1,3,5-trisulphonate)	401-650-1	85665-96-9	Skin Sens. 1	H317	GHS07 Wng	H317	CLP00/
016-042-00-8	tetrasodium 5-benzamido-3-(5-(4-fluoro-6-(1-sulphonato-2-naphthylamino)-1,3,5-triazin-2-ylamino)-2-sulphonatophenylazo)-4-hydroxynaphthalene-2,7-disulphonate	400-790-0	85665-97-0	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317	CLP00/

016-038-00-6	disodium 6-(4-chloro-6-( <i>N</i> -methyl)-2-toluidino)-1,3,5-triazin-2-ylamino)-1-hydroxy-2-(4-methoxy-2-sulphonatophenylazo)naphthalene-3-sulphonate	400-380-1	86393-35-3	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
607-124-00-X	2-hydroxyethyl methacrylate	212-782-2	868-77-9	Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1	H319 H315 H317	GHS07 Wng	H319 H315 H317			D	CLP00/
005-014-00-0	4-formylphenylboronic acid	438-670-5	87199-17-5	Skin Sens. 1	H317	GHS07 Wng	H317				ATP01/
607-662-00-5	methyl 2-(acetylaminio)-3-chloropropionate	442-860-3	87333-22-0	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410				ATP01/
607-432-00-4	<i>S</i> -metolchlor; reaction mass of ( <i>S</i> )-2-chloro- <i>N</i> -(2-ethyl-6-methyl-phenyl)- <i>N</i> -(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] ( <i>R</i> )-2-chloro- <i>N</i> -(2-ethyl-6-methyl-phenyl)- <i>N</i> -(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2]	- [1] - [2]	87392-12-9 [1] 178961-20-1 [2]	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410				CLP00/
006-071-00-4	cyclooct-4-en-1-yl methyl carbonate	401-620-8	87731-18-8	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
607-666-00-7	(2 <i>S</i> )-5-(benzoyloxy)-2-(1,3-dioxo-1,3-dihydro-2 <i>H</i> -isotridol-2-yl)-5-oxopentanoic acid	443-560-5	88784-33-2	Eye Irrit. 2	H319	GHS07 Wng	H319				ATP01/
613-132-00-3	phenyl <i>N</i> -(4,5-dimethoxy-pyrimidin-2-yl)carbamate	406-600-2	89392-03-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/
603-136-00-3	2-(2,4-dichlorophenyl)-2-(2-propenyl)oxirane	411-210-0	89544-48-9	Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H315 H317 H400 H410	GHS07 GHS09 Wng	H315 H317 H410				CLP00/
029-007-00-7	(trisodium 2-(3-(6-(2-chloro-5-sulfonato)anilino)-4-(3-carboxypyridin-1,3,5-triazin-2-ylamino)-2-oxido-5-sulfonatophenylazo)phenylmethylazo)-4-sulfonatobenzoato)kopper(3-)) hydroxide	404-670-9	89797-01-3	Skin Sens. 1	H317	GHS07 Wng	H317			G	CLP00/
647-015-00-4	amylase, $\alpha$ -	232-565-6	90000-90-2	Resp. Sens. 1	H334	GHS08	H334				CLP00/
647-001-00-8	glucosidase, $\beta$ -	232-589-7	9001-22-3	Resp. Sens. 1	H334	GHS08	H334				CLP00/
647-002-00-3	cellulase	232-734-4	9012-54-8	Resp. Sens. 1	H334	GHS08	H334				CLP00/
604-036-00-3	4,4'-oxybis(ethylphenol)diphenol	404-590-4	90884-29-0	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/
605-021-00-4	formaldehyde, reaction products with butylphenol	294-145-9	91673-30-2	Skin Sens. 1	H317	GHS07 Wng	H317				CLP00/
607-208-00-6	4,8,12-trimethyltrideca-3,7,11-trienoic acid, mixed isomers	403-000-2	91853-67-7	Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H315 H400 H410	GHS07 GHS09 Wng	H315 H410				CLP00/
607-125-00-5	2-hydroxypropyl methacrylate; [1] 3-hydroxypropyl methacrylate [2]	213-090-3 [1] 220-426-2 [2]	923-26-2 [1] 2761-09-3 [2]	Eye Irrit. 2 Skin Sens. 1	H319 H317	GHS07 Wng	H319 H317			C D	CLP00/
603-092-00-6	2-methyl-4-phenylpentanol	402-770-7	92585-24-5	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411				CLP00/



616-169-00-4	4-[4-(2,2-dimethylpropanamido)phenylazo-3-(2-chloro-5-(2-(3-pentadecylphenoxy)butylamido)anilino)-1-(2,4,6-trichlorophenyl)-2-pyrazoline-5-one	420-220-4	92771-56-7	Skin Sens. 1 Aquatic Chronic 4	H317 H413	GHS07 Wng	H317 H413			ATP01/
609-060-00-8	4-[(3-hydroxypropyl)amino]-3-nitrophenol	406-305-9	92952-81-3	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411			CLP00/
605-032-00-4	3-[3-(4-fluorophenyl)-1-(1-methylethyl)-H]-indol-2-yl]-( <i>E</i> )-2-propenal	425-370-4	93957-50-7	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			ATP01/
609-061-00-3	( <i>E,Z</i> )-4-chlorophenyl(cyclopropyl)ketone O-(4-nitrophenylmethyl)oxime	406-100-4	94097-88-8	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			CLP00/
607-545-00-9	1,2-dimethyl-3-(1-methylethyl)cyclopentyl acetate	424-070-0	94346-09-5	Skin Irrit. 2 Aquatic Chronic 2	H315 H411	GHS07 GHS09 Wng	H315 H411			ATP01/
607-179-00-X	(benzothiazol-2-ylthio)succinic acid	401-450-4	95154-01-1	Skin Sens. 1	H317	GHS07 Wng	H317			CLP00/
613-136-00-6	<i>N</i> -cyclohexylbenzothiazole-2-sulphenamide	202-411-2	95-33-0	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410			CLP00/
603-061-00-7	tetrahydro-2-furylmethanol; tetrahydrofurfuryl alcohol	202-625-6	97-99-4	Eye Irrit. 2	H319	GHS07 Wng	H319			CLP00/
613-276-00-8	1-(2-chlorophenyl)-1,2-dihydro-5 <i>H</i> -tetrazol-5-one	426-110-2	98377-35-6	Skin Sens. 1 Aquatic Chronic 3	H317 H412	GHS07 Wng	H317 H412			ATP01/
613-227-00-0	(±)-[ <i>(R,R^*)</i> and ( <i>R,S^*)</i> ]-6-fluoro-3,4-dihydro-2-oxiranyl-2 <i>H</i> -1-benzopyran	419-600-2	99199-90-3	Skin Sens. 1 Aquatic Chronic 2	H317 H411	GHS07 GHS09 Wng	H317 H411			CLP00/

